Stockwinners Market Radar for January 17, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:11 EST Albertsons says to pay special dividend after Washington Supreme Court ruling - The company states: "Albertsons announced that the State of Washington's Supreme Court has denied a motion by the Attorney General of the State of Washington to hear an appeal from the trial court's denial of its request to enjoin the Company from paying its previously announced $6.85 per common share Special Dividend, originally scheduled to be paid November 7, 2022. The temporary restraining order preventing the payment of the Special Dividend has been lifted as a result of the decision. Albertsons Cos. will immediately begin the process of paying the Special Dividend and amounts will be distributed as soon as practicable to stockholders of record as of the close of business on October 24, 2022."

20:54 EST Horizon Therapeutics CFO sells $4.09M in common stock - In a regulatory filing, Horizon Therapeutics disclosed that its CFO Aaron Cox sold 36K shares of common stock on January 13th in a total transaction size of $4.09M.

20:14 EST Cathie Wood's ARK Investment bought 210.4K shares of Cerus today

19:39 EST Privia Health announces launches of ACOs in Delaware and North Carolina - Privia Health Group announced it has launched two new Accountable Care Organizations, or "ACOs," now including providers in Delaware and North Carolina, which are participating in the Medicare Shared Savings Program, or "MSSP." This expands the total number of Privia-owned ACOs to nine, serving beneficiaries across the District of Columbia and ten states, including California, Delaware, Florida, Georgia, Maryland, Montana, North Carolina, Tennessee, Texas, and Virginia. Effective January 1, 2023, the Privia ACOs will now include more than 2,500 independent providers delivering care to over 191,700 Medicare beneficiaries. Five of the nine ACOs are participating in the MSSP Enhanced Track with "substantial, potential upside and downside financial risk," the company stated. "As Privia continues to expand our national footprint, we are proud to continue launching new ACOs and expanding our relationship with CMS and the MSSP program. We remain focused on building scaled provider networks nationwide and enabling our providers to transition profitably and intelligently to increased risk in value-based programs over time," said Mark Foulke, Privia Health Executive Vice President Transformational Value-Based Care.

18:48 EST Clear Channel Outdoor up 7% as Ares Management discloses $460K purchase of stock

18:44 EST Prosperity Bancshares announces roughly 4.6M share buyback - Prosperity Bancshares announced that its Board of Directors authorized a stock repurchase program under which the company may repurchase up to 5%, or approximately 4.6M shares, of its outstanding common stock over a one-year period expiring on January 17, 2024, at the discretion of management. Repurchases under this program may be made from time to time in open market transactions, and pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Repurchases under this program also may be made in transactions outside the safe harbor provided by Rule 10b-18 during a pending merger, acquisition or similar transaction. The timing and actual number of shares repurchased will depend on a variety of factors including price, corporate and regulatory requirements, market conditions, and other corporate liquidity requirements and priorities. Any repurchased shares will be held by the company as authorized but unissued shares.

18:09 EST SmileDirectClub jumps 13% after announcing realignment of global workforce - SmileDirectClub shares are up 13% or 7c to 67c per share in after-hours trading after announcing realignment of global workforce and operating programs.

18:05 EST Permian Resources reaffirms Q4 outlook - The Company is not adjusting its previously announced Q4 and FY23 preliminary outlook as a result of these transactions and plans to issue FY23 guidance concurrent with its Q4 and FY22 earnings results.

18:01 EST Parts iD is evaluating evaluating potential strategic alternatives - PARTS iD announced that its Board of Directors, led by its Finance & Business Development Committee, is evaluating potential strategic alternatives to maximize shareholder value. As part of the process, the Board is considering a full range of strategic alternatives, which may include financing alternatives, merger, reverse merger, other business combinations, sale of assets, licensing, or other transactions. PARTS iD has retained Canaccord Genuity as its financial advisor and DLA Piper as its legal counsel to assist in evaluating potential strategic alternatives. There can be no assurance that the evaluation of strategic alternatives will result in any potential transaction, or any assurance as to its outcome or timing.

17:44 EST Oversight Board overturns Meta decisions in 'gender identity and nudity' cases - The Oversight Board has overturned Meta's original decisions to remove two Instagram posts depicting transgender and non-binary people with bare chests. It also recommends that Meta change its Adult Nudity and Sexual Activity Community Standard so that it is governed by clear criteria that respect international human rights standards. In this decision, the Oversight Board considers two cases together for the first time. Two separate pieces of content were posted by the same Instagram account, one in 2021, the other in 2022. The account is maintained by a US-based couple who identify as transgender and non-binary. Both posts feature images of the couple bare-chested with the nipples covered. The image captions discuss transgender healthcare and say that one member of the couple will soon undergo top surgery (gender-affirming surgery to create a flatter chest), which the couple are fundraising to pay for. Following a series of alerts by Meta's automated systems and reports from users, the posts were reviewed multiple times for potential violations of various Community Standards. Meta ultimately removed both posts for violating the Sexual Solicitation Community Standard, seemingly because they contain breasts and a link to a fundraising page. The users appealed to Meta and then to the Board. After the Board accepted the cases, Meta found it had removed the posts in error and restored them. Reference Link

17:22 EST Castle up 1.5% after announcing presentation for dermatology conference - Castle Biosciences shares up 40c or +1.48% to $27.46 per share in after-hours trading after announcing the company will share new data supporting the clinical value of Castle's skin cancer test portfolio at the 2023 Winter Clinical Dermatology Conference - Hawaii , being held Jan. 13-18 in Kohala Coast, Hawaii.

17:18 EST Pan American Silver reports FY22 silver production of 18.5M oz - The company states: "Consolidated silver production in 2022 of 18.5 million ounces was within the revised guidance range of 18.0 to 18.5 million ounces provided on November 9, 2022, and only modestly below the original guidance of 19.0 to 20.5 million ounces provided on February 23, 2022. Consolidated gold production in 2022 of 552.5 thousand ounces was within the original guidance range of 550.0 to 605.0 thousand ounces provided on February 23, 2022. Consolidated zinc production in 2022 of approximately 38 thousand tonnes was within guidance of 35 - 40 thousand tonnes, lead production of approximately 18 thousand tonnes was above guidance of 15 - 17 thousand tonnes, and copper production of approximately 5 thousand tonnes was modestly below guidance of 5.5 - 6.5 thousand tonnes, based on the original guidance ranges provided on February 23, 2022." CEO Michael Steinmann: "I am very pleased with our team's efforts to deliver production results in line with our guidance for 2022. Q4 2022 results were led by strong production at Shahuindo and La Arena, as expected."

17:10 EST Bausch + Lomb acquires AcuFocus, terms not disclosed - Bausch + Lomb and AcuFocus, a privately held ophthalmic medical device company, announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus.

17:02 EST BeiGene presents new research from Tislelizumab program at 2023 ASCO - BeiGene "will share clinical data and patient-reported outcomes for its PD-1 inhibitor, tislelizumab, at the 2023 ASCO Gastrointestinal Cancers Symposium, notably, an oral presentation for interim results of the global pivotal phase 3 trial RATIONALE 305 of tislelizumab in combination with chemotherapy in first-line gastric or gastroesophageal junction cancer. At the interim analysis, RATIONALE 305 trial met one of the primary endpoints of overall survival in patients with G/GEJ whose tumors express PD-L1."

16:46 EST Amtech Systems acquires Entrepix for $35M - Amtech Systems announced the acquisition of Entrepix, a globally recognized expert in chemical mechanical polishing and wafer cleaning. Entrepix is expected to expand Amtech's market opportunity and accelerate growth in the front-end wafer processing market, including silicon carbide applications. Entrepix reported revenues of $26.7M on a trailing twelve months basis ended December 31, 2022. The transaction closed on January 17 for a purchase price of $35M, funded with available cash and a term loan with UMB Bank. The acquisition was structured through a reverse triangular merger wherein Amtech acquired Entrepix, resulting in Entrepix becoming a wholly owned subsidiary of the Company. The purchase price is subject to a customary working capital adjustment.

16:39 EST Arch Therapeutics announces 1-for-200 reverse stock split - Arch Therapeutics announced that it will effect a 1-for-200 reverse stock split of its outstanding and authorized common stock, effective at 5:00 p.m. on January 17, 2023. Arch's common stock will continue to trade on the OTCQB under the symbol "ARTHD" and under a new CUSIP number, 03939W 208. Arch's common stock will begin trading on a reverse stock split-adjusted basis on the OTCQB when the market opens on January 18, 2023.

16:33 EST Aridis to present AR 501 Phase 2 trial update for CF treatment at KOL - Aridis Pharmaceuticals announced its participation in Key Opinion Leader, KOL, event focusing on the anti-infective treatment landscape in cystic fibrosis CF and the Company's Phase 2a trial of AR-501 in CF patients. AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in CF patients. Carl Byrnes, Managing Director and Senior Research Analyst at Northland Capital Markets will host and moderate the virtual KOL. Aridis' Chief Medical Officer Hasan Jafri, MD, and CEO Vu Truong, PhD, will also participate in the event.

16:24 EST United Airlines ends 2022 with available liquidity of $18.2B

16:19 EST United Airlines sees FY23 capacity up 'high teens' y/y - Sees FY23: TRASM ~flat, y/y: Adjusted pre-tax margin ~9%; Average aircraft fuel price per gallon $2.85-$2.90.

16:18 EST ICF International appoints Mark Lee as Chief Technology Officer - ICF announced that Mark Lee has been named Chief Technology Executive, and Jennifer Welham will lead ICF's health, human services and workforce business. In his new role, Lee will lead a new group focused on increasing the company's technology capabilities and maintaining the strong growth momentum of ICF's U.S. federal digital modernization business. Lee will also oversee a new company-wide CTO organization to help drive further technology growth and innovation across all of the firm's markets. Previously, Lee served as the executive vice president of ICF's public sector business where he successfully integrated several technology acquisitions and added over 1,000 new technologists to the firm. Lee has been with ICF for 25 years and has held many leadership roles across the company's public sector business, including previously serving as the head of business development and the disaster management division. Prior to this, he led the climate, sustainability, environmental health and surface transportation businesses and has extensive experience supporting a wide range of clients in addressing technology, regulatory, workforce development and policy challenges.

16:16 EST Universal Display, Seiko Epson announce OLED evaluation agreement - Universal Display Corporation announced an OLED evaluation agreement with Seiko Epson Corporation. Under the agreement, Universal Display will supply its proprietary phosphorescent OLED materials and technology to Epson for AR/VR display applications. Details and financial terms of the agreement have not been disclosed. "We are pleased to continue our partnership with Japanese panel maker Seiko Epson," said Steven V. Abramson, President and Chief Executive Officer of Universal Display Corporation. "Our mission is to enable our customers and the OLED industry with our highly-efficient, high-performing proprietary OLED technologies and UniversalPHOLED materials. We look forward to further collaborating with Epson as the proliferation of OLEDs is expected to broaden and grow in the consumer electronics landscape."

16:12 EST Core Laboratories proposes redomestication of parent company to U.S. - Core Laboratories announces the company's Board of Directors has approved a plan to reorganize the company's corporate structure, which will include redomestication of the parent company from the Netherlands to the United States. The company and its Board believes that the Redomestication will enhance shareholder value over the long-term through simplifying the corporate structure, improving operational efficiencies and reducing administrative costs. The Redomestication will, if completed, change the Company's jurisdiction of organization from the Netherlands to the State of Delaware. Following shareholder approval, the Redomestication will be completed through a series of steps, as follows: (i) Core Laboratories N.V. will merge with and into Core Laboratories Luxembourg S.A., with Core Laboratories Luxembourg S.A. surviving, and (ii) as soon as practicable thereafter, Core Laboratories Luxembourg S.A. will migrate out of Luxembourg and redomesticate into the State of Delaware, as Core Laboratories Inc., which will become Core's ultimate parent company. Upon completion of the transaction, Core Laboratories N.V. shareholders will hold one share of Common Stock of Core Lab Delaware for each Common Share of Core Laboratories N.V. owned immediately prior to the Redomestication. Core Lab N.V. Common Shares will continue to trade on the New York Stock Exchange up to and including the effective date of the Redomestication. Following the effective date of the Redomestication, shares of Common Stock of Core Lab Delaware will be listed on the NYSE under the ticker symbol "CLB". The Company's shares will continue to trade uninterrupted during and upon completion of the Redomestication. Benefits from the Redomestication will include: (i) a reduced corporate footprint and a reduction in regulatory requirements associated with audited financial statements, financial reporting, and compliance with other statutory regulations, (ii) improved efficiencies and opportunities in the Company's corporate treasury, cash management, risk management and tax functions, and (iii) a simplified and more efficient tax structure. The Redomestication requires a shareholder vote for approval, which will be conducted through an extraordinary general meeting of Core Lab shareholders, which is anticipated to occur early in the second quarter of 2023.

16:10 EST United Airlines jumps 5% to $53.91 after Q4 results, FY23 guidance top estimates

16:07 EST ZW Data Action Technologies announces reverse stock split - ZW Data Action Technologies announced that its board has approved a reverse stock split of its common stock, at a ratio of 1-for-5. The split is expected to become effective on January 18, and the shares are expected to begin trading on the split-adjusted basis on the Nasdaq under the company's existing trading symbol "CNET" at market open on January 20, upon Nasdaq's approval.

16:06 EST Lesaka announces departure of Alex Smith, Chief Accounting Officer - Lesaka Technologies announced that Alex M.R. Smith is leaving the company to pursue other opportunities. Smith's last day of employment will be March 01. During this notice period, Smith will assist the company in consolidating the roles and responsibilities of Chief Accounting Officer into the ambit of Lesaka's highly experienced Finance team.

16:02 EST United Airlines reports Q4 capacity down 9% vs. 4Q19 - Reports Q4: TRASM of up 26% compared to fourth-quarter 2019. CASM of up 21%, and CASM-ex of up 11%, compared to fourth-quarter 2019. Operating margin of 11.1%, adjusted operating margin of 11.2%, both up over 2 pts. compared to fourth-quarter 2019. Pre-tax margin of 9.1%, adjusted pre-tax margin of 9.0%, both up and around 1 pt. compared to fourth-quarter 2019. Average fuel price per gallon of $3.54.

15:49 EST TIM SA trading resumes

15:15 EST VGFC Stock trading resumes

13:45 EST Bit Brother Ltd trading halted, volatility trading pause

13:24 EST S&P Global to sell Engineering Solutions business to KKR for $975M - S&P Global (SPGI) announced that it has entered into an agreement to sell its Engineering Solutions business to investment funds managed by KKR (KKR) for $975M in cash, subject to customary purchase price adjustments. S&P Global currently anticipates the divestiture to result in after-tax proceeds of approximately $750M, which proceeds are expected to be used to fund share repurchases. The agreement follows S&P Global's announced intent in November 2022 to divest the business. Engineering Solutions provides data, technology, and insights that allow over 6,000 global customers and 650,000 users to optimize workflows and end-user experiences. Its products enable engineers, builders, and architects in many industries to access the data and insights they need to deliver complex projects and new products. KKR is making the investment through its North America Fund XIII. Engineering Solutions became part of S&P Global following the company's merger with IHS Markit early last year. The transaction, which is subject to receipt of required regulatory approvals and satisfying other customary closing conditions, is expected to close by the end of the second quarter of 2023.

13:04 EST Apple to assess compliance with human rights commitments, NYC Comptroller says - The Office of the New York City Comptroller, New York City Retirement Systems, and a coalition of investors jointly announced an agreement has been reached with Apple to conduct a third-party assessment overseen by its board of directors of the company's adherence to its Human Rights Policy, with a focus on the rights of workers to organize and bargain collectively. It will also review management's practices when employees seek to exercise their rights to form or join or refrain from joining a union. Apple has agreed to publicly release the report by the end of 2023. Apple reached an agreement with the five New York City Retirement Systems, Trillium ESG Global Equity Fund, SOC Investment Group, Parnassus Investments, Service Employees International Union Master Trust Pension Plan and the Greater Manchester Pension Fund. The coalition of investors represents approximately 53M Apple shares valued at $7B. The investor coalition filed a shareholder proposal with Apple in September 2022, calling for such an assessment, the office of the comptroller stated. Reference Link

12:31 EST Oak Street Health down 7% in afternoon trading - Afternoon weakness in shares of Oak Street Health (OSH) is being attributed to a report from Axios that said analysts, bankers and advisers do not think CVS Health (CVS) will be likely to buy the medicare-focused primary care operator, according to contacts.

12:10 EST U.S. video game consumer spending fell 2% y/y in December, says NPD - NPD analyst Mat Piscatella said that U.S. consumer spending on video game content, hardware and accessories totaled $7.6B in December 2022, an increase of 2% when compared to a year ago. Hardware spending grew 16%, offsetting declines in both content and accessories. 2022 spending totaled $56.6B, 5% below 2021 levels despite growth in hardware and subscription content spend. Factors impacting 2022 spending included continued supply constraints of console hardware, a relatively light slate of new premium releases, and macroeconomic conditions. Publicly traded companies in the space include Microsoft (MSFT), Sony (SONY), Activision Blizzard (ATVI), Electronic Arts (EA), GameStop (GME), Nintendo (NTDOY), Take-Two (TTWO), Tencent (TCEHY) and Ubisoft (UBSFY). Reference Link

12:00 EST Biotie Therapies falls -8.8% - Biotie Therapies is down -8.8%, or -$2.94 to $30.40.

12:00 EST Roblox rises 12.6% - Roblox is up 12.6%, or $4.17 to $37.38.

12:00 EST BIT Mining rises 67.1% - BIT Mining is up 67.1%, or $2.06 to $5.13.

11:27 EST VGFC Stock trading halted, news pending

11:22 EST National Instruments confirms receipt of acquisition proposal from Emerson - NI (NATI) confirmed that it has received a proposal from Emerson (EMR) to acquire the Company for $53 per share in cash, following a prior proposal from Emerson to acquire the Company for $48 per share. The company said, "As previously publicly announced by the Company on January 13, NI's Board of Directors has initiated a review and evaluation of strategic options with the intent to unlock and maximize shareholder value. This strategic review process includes robust solicitation of interest from potential acquirors. NI's Board of Directors will evaluate Emerson's proposal within the context of the ongoing strategic review process, consistent with its fiduciary duties and in consultation with its financial and legal advisors. NI welcomes Emerson's interest and participation in the process, as NI has previously informed Emerson. NI determined to affirmatively initiate, announce and pursue a comprehensive strategic review process inclusive of other counterparties rather than negotiate exclusively with Emerson, which NI believes would be detrimental to shareholder interests. NI notes Emerson's expressed disappointment in this effort to maximize NI shareholder value. NI is focused on conducting its strategic review process in a manner that provides all interested parties with the opportunity to fairly participate on a level playing field, which we believe is the best way to ensure that the process can maximize value for all shareholders. NI appreciates the input and support the Company has received from shareholders regarding the ongoing process." BofA Securities and Wachtell, Lipton, Rosen & Katz are acting as NI's financial and legal advisor, respectively.

10:42 EST James Hardie names Tim Beastrom as chief legal counsel - James Hardie Industries announced the appointment of Tim Beastrom as Chief Legal Counsel, and Joel Wasserman as Vice President, Corporate Communications and Global Brand Management, effective immediately. As members of the global executive team, Beastrom and Wasserman will report directly to CEO Aaron Erter.

10:29 EST Gold Resource sold 42,757 GEOs in 2022 - Gold Resource Corporation sold a total of 30,119 ounces of gold and 1,057,209 ounces of silver in 2022 for a gold equivalent total of 42,757 gold equivalent ounces. Additionally, during the year the Company sold 14,157 tonnes of zinc, 1,348 tonnes of copper, and 5,391 tonnes of lead contributing to a strong cash balance of over $23M. Allen Palmiere, President and CEO said "Despite global challenges faced this year, such as inflation, and localized challenges such as ground support and ventilation, gold and silver production at the Don David Gold Mine in Mexico still ended the year above guidance. While our grade profile is expected to decline in 2023, we continue to identify and implement improvement opportunities, including collaborating with local communities to ensure sustainability. Work continues with the feasibility study to advance the Back Forty Project in Michigan and once completed, preparation of State of Michigan permits will follow. In addition to the feasibility study work, we continue to focus on engaging with the local community."

10:03 EST Peloton appoints Leslie Berland as CMO - Peloton announced the appointment of Leslie Berland as Peloton's Chief Marketing Officer, effective January 18, 2023. Berland brings more than two decades of strategic and creative marketing expertise for iconic brands. She will report to CEO Barry McCarthy and serve as a member of the leadership team, overseeing brand and product marketing, creative, consumer insights, membership, and global communications. Berland previously served as CMO at Twitter.

10:02 EST MARAEY signs agreement with Marriott to build three distinct hotels in Marica - MARAEY announced that it has signed an agreement with Marriott International, Inc., to build three distinct hotels in Marica, Rio de Janeiro. The projects are strategically located to create an international tourist destination focused on sustainability and innovation, as well as high-end service and experiences. Situated just 45 km from Rio de Janeiro, the three-hotel complex is anticipated to mark the introduction of the exclusive Ritz-Carlton Reserve brand to Brazil and South America. In addition, the planned JW Marriott is expected to be one of the brand's first all-inclusive hotels in the world. The innovative Rock in Rio, Autograph Collection, is slated to be the first thematic hotel bearing the name of the popular festival that attracts thousands of fans. With MARAEY's estimated investment of approximately $360M, the properties are expected to feature more than 1,100 rooms, generate more than 16,000 direct and indirect jobs during the building phase, and create over 3,500 positions once operational. An Economic Impact Study, developed by Abacus Group, indicated the hotels will catalyze economic and tourism expansion in Rio de Janeiro state and Brazil, with a projected 300,000 direct and 150,000 indirect visitors per year.

10:00 EST ProShares UltraShort Bloomberg Natural Gas falls -7.6% - ProShares UltraShort Bloomberg Natural Gas is down -7.6%, or -$3.05 to $37.00.

10:00 EST Archer announces term sheet to potentially acquire Baker Hughes unit in U.K. - Archer Limited announced it has signed a term sheet with Baker Hughes Limited to potentially acquire Baker Hughes' coil tubing and pumping, or "CT&P," business in the United Kingdom. "The CT&P business fits well within Archer's overall strategy to grow our drilling and well services in UK and to further grow our integrated P&A service offering. Baker Hughes is divesting the CT&P business as a part of a remedy package offered to the UK Competition and Markets Authority. The CMA is undertaking a public consultation process with Archer and one other potential purchaser, which is expected to conclude by February 1, 2023. The contemplated transaction is subject to Archer being selected as the preferred purchaser by Baker Hughes, definitive agreements, final approval by the CMA, and Archer Board approval," Archer Limited stated.

10:00 EST Roblox rises 11.2% - Roblox is up 11.2%, or $3.73 to $36.94.

10:00 EST Silvergate Capital rises 18.0% - Silvergate Capital is up 18.0%, or $2.37 to $15.57.

09:51 EST Tenet Healthcare up 1% in early trading after Einhorn reveals long position

09:47 EST ProShares UltraShort Bloomberg Natural Gas falls -8.4% - ProShares UltraShort Bloomberg Natural Gas is down -8.4%, or -$3.38 to $36.67.

09:47 EST X Financial falls -18.3% - X Financial is down -18.3%, or -72c to $3.21.

09:47 EST Turkcell rises 13.8% - Turkcell is up 13.8%, or 60c to $4.95.

09:39 EST Goldman Sachs to scale platform solutions business, says CEO Solomon

09:37 EST Volcon: Stag pre-production orders recently eclipsed $116M - Volcon (VLCN) announced that the Stag, the company's flagship all-wheel drive, fully electric UTV, recently eclipsed $116,000,000 in pre-production orders with over 90% of these orders coming from its network of 151 dealers across the US, and its six distributors in South and Central America and the Caribbean region. The Stag will be the first fully electric UTV in its class and the first and currently only UTV to be powered by General Motors' (GM) Ultium electric propulsion system technologies.

09:36 EST Goldman postponed plans to offer checking to wealth management customers

09:35 EST Novo Integrated Sciences continues to work to close SWAG deal - Novo Integrated Sciences provided an update with respect to certain actions and events, as follows: As previously reported, on December 23, 2022, Novo entered into a Share Purchase Agreement with SwagCheck and the shareholders of SWAG, pursuant to which Novo agreed to purchase 100% of SWAG's outstanding shares. SWAG holds a specific right of purchase of a precious gem collection as provided for in an agreement between SWAG and a Court-appointed Successor Receiver for the United States District Court for the Central District of California. Pursuant to the terms of the SWAG Agreement, as amended, the SWAG Agreement was to close no later than January 10, 2023. Although the SWAG Agreement has not yet closed, the parties continue to work together with the intention of closing the transaction. Between January 5, 2023 and January 16, 2023, the Company issued 2,469,348 common shares to certain warrant holders upon exercise of their warrants. Between January 5, 2023 and January 16, 2023, the Company issued 17,277,700 common shares to certain note holders upon conversion of their notes. As of January 16, 2023, the Company's issued and outstanding common share count is 59,637,859. The Company and its independent auditor are working diligently to complete the audit for the Company's fiscal year ended August 31, 2022, and the Company intends to file its Annual Report on Form 10-K in the near future.

09:33 EST Tyler Technologies helps develop software for Delray Beach, Florida - Tyler Technologies announced that the city of Delray Beach, Florida, has successfully gone live with Tyler's My Civic and Enterprise Service Requests software, branded MyDelrayBeach. The city had been interested in developing a mobile app for some time as part of a greater push to advance technology across the city. The launch of My Civic is the first phase in the city's overall technology upgrade. Tyler's Enterprise Permitting & Licensing software will be deployed in the next phase. "We are pleased to support Delray Beach's mission to advance technology across the city," said Greg Savard, general manager of Tyler's civic services business unit. "The app brings great value to residents, who now have direct, two-way communication with the city. The app helps residents stay informed, leading to stronger and more engaged communities."

09:31 EST American Resources' ReElement enters agreement with Continental Lithium - American Resources announced that its wholly-owned subsidiary, ReElement Technologies entered into a memorandum of understanding with Continental Lithium to begin trial shipments of lithium spodumene ore to ReElement Technologies' Noblesville, Indiana facility to refine into high-purity lithium carbonate or lithium hydroxide using the Company's patented and revolutionary multi-mode chromatography technology. Post initial material testing, the parties intend to work towards jointly developing a ReElement lithium refinement facility in Nigeria to locally process and purify lithium spodumene. The initial trials will consist of 28 metric ton increments of 5% to 8% grade lithium spodumene concentrate that is produced at Continental Lithium's Nigerian mines and shipped to Noblesville, Indiana to be processed through ReElement's facility to a 99.9% or greater, ultra-high pure lithium carbonate. ReElement will sell the purified lithium carbonate or lithium hydroxide into the domestic battery manufacturing marketplace. The MOU outlines this supply of spodumene as well as the steps of jointly building and operating a ReElement Technologies lithium refining facility in Africa that is centrally located around Continental Lithium's spodumene mines, which will result in reduced transportation costs, creation of high-quality jobs, and reduction in the environmental footprint of the lithium production life cycle. The lithium refined at the facility will be solid either locally or into the United States domestic battery industry.

09:28 EST Robinhood announces formation of Sherwood Media - Robinhood Markets announced the formation of Sherwood Media, LLC, a new subsidiary that will be a home for news and information about the markets, economics, business, technology, and the culture of money. Sherwood Media, LLC will build on the success of Snacks - a daily markets and business newsletter - which has one of the largest audiences in the country. Tens of millions of people read Snacks each week for its incisive, illuminating views on the biggest news of the day. Joshua Topolsky - founder and former Editor-in-chief of the technology news network The Verge, co-creator of its parent company Vox Media, and former Chief Digital Content Officer at Bloomberg - will serve as the Editor-in-chief and President of Sherwood Media. Sherwood Media, LLC will launch a suite of new editorial offerings throughout 2023, complementing Snacks with more always-on news updates and analysis, original reporting, new newsletter offerings, social-first content, and live events. Additionally, starting with Snacks, Sherwood Media, LLC will offer exclusive advertising opportunities with select partners.

09:27 EST Fintech Ecosystem announces extension of deadline to complete combination - Fintech Ecosystem Development announced that its board of directors has elected to extend the date by which FEXD has to consummate a business combination from January 21, 2023 to April 21, 2023, as permitted under FEXD's Amended and Restated Certificate of Incorporation. In connection with the Extension, FEXD'S sponsor, Revofast LLC, has notified FEXD that it intends to deposit an aggregate of $1,150,000 into FEXD's trust account on or before January 21, 2023. The Extension will provide FEXD with additional time to complete its proposed business combination with fintech companies Rana Financial and Mobitech International.

09:27 EST Heritage Insurance authorizes new $10.0M share repurchase plan - Heritage Insurance authorized a new share repurchase plan of $10.0M commencing upon the December 31, 2022 expiration of the prior $25.0M share repurchase program. Under the new Share Repurchase Plan, the company is authorized to repurchase shares at any time until December 31, 2023.

09:24 EST Biotricity signs agreement with group purchasing organization - Biotricity signed an agreement with a leading group purchasing organization for national distribution of its cardiac monitoring solutions, Bioflux and Biotres. Both Bioflux and Biotres are designed for cardiologists to diagnose and monitor their patients remotely. GPO's are entities comprised of businesses organized to purchase materials or supplies from vendors in larger volumes to gain efficiency. In this case, the GPO is comprised of hundreds of small, independent US hospitals, private clinics, and medical offices that purchase medical devices and supplies at scale.

09:23 EST Disney says Peltz 'lacks skills and experience' to help board deliver value - In slides responding to investor Nelson Peltz, Disney contended that the company's board "is the right board for shareholders" and argued that Peltz "does not understand Disney's business and lacks the skills and experience to assist the board in delivering shareholder value in a rapidly shifting media ecosystem." Reference Link

09:22 EST Xenetic announces notice of allowance for Canadian patent on DNase enzyme - Xenetic Biosciences announced that the Canadian Intellectual Property Office has issued a notice of allowance for Patent Application No. 3,001,543 titled, "Method to Improve Safety and Efficacy of Anti-Cancer Therapy." A patent from the recently allowed application is expected to be issued in the coming months. The allowed patent covers claims including use of a therapeutically effective amount of a DNase enzyme for preventing or ameliorating a toxicity associated with a cytostatic and/or cytotoxic chemotherapy in a subject suffering from a cancer and received or deemed to receive said chemotherapy, wherein said amount of the DNase enzyme is effective to prevent or ameliorate at least one side effect of said chemotherapy. The Company's interventional DNase based oncology platform is aimed at improving outcomes of existing treatments, including immunotherapies. The Company's exclusive license to CLS Therapeutics' intellectual property for uses of DNases in cancer include systemic co-administration of DNases along with standard therapies, including chemotherapy, radiation and checkpoint inhibitors, or along with conventional chimeric antigen receptor T therapies. Xenetic is focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally advanced or metastatic solid tumors.

09:18 EST Duos Technologies releases six additional AI detection models - Duos Technologies Group announced the release of six new artificial intelligence detection models for use with the Company's Railcar Inspection Portal solution. The new offerings are the latest additions to a growing catalog of automated inspection tools that allow railcar operators to detect a wide variety of defects such as the condition of air hoses, sill steps, hand brakes, wheels and uncoupling levers. Other detections relate to coupler heights and unsecured pneumatic unloader caps all of which are operational and safety components for freight railcars. These detections can help to reduce Line-Of-Road delays, a key metric for railroad operations.

09:16 EST Enovis expands launches DynaClip bone staples - Enovis Corporation announced the launch of the DynaClip Delta and DynaClip Quattro bone staples, the latest additions to the Company's growing foot and ankle portfolio and the DynaClip family of bone fixation systems.

09:15 EST Clearmind Medicine announces results from third part of preclinical study - Clearmind Medicine announced additional positive pre-clinical results in its ongoing series of research studies conducted to illuminate the tremendous potential of MEAI and its effect on substance-use-disorder. The latest in-vivo studies examined the effect of MEAI on the natural reward process as it pertains to cocaine addiction. The pre-clinical studies were led by Professor Gal Yadid from the Gonda Multidisciplinary Brain Research Center at Bar Ilan University in Israel. As previously announced, Clearmind's proprietary MEAI at a dose of 5mg/kg, demonstrated unique ability to decrease cocaine craving and potentially become the first dedicated cocaine addiction treatment. The latest research studies were designed to evaluate the effects of MEAI on natural reward, as reward-based positive reinforcement is a shared evolutionary survival strategy across species. However, in drug addiction, reward seeking becomes maladaptive and endangers survival. The purpose of this in-vivo study, was to conclude whether MEAI uses the same mechanisms that underlie the seeking of both drug and natural rewards (such as sucrose). The results demonstrated that natural reward was maintained in the MEAI-treated rats, thus showing that the effect of MEAI on drug-seeking is not related to the general reward system.

09:13 EST Shineco entered into framework agreement relating to Wintus acquisition - Shineco announced that on January 13, 2023, the Company entered into a non-binding framework agreement with certain shareholders of Dream Partner to acquire 80% equity interests of Dream Ltd., which indirectly owns 100% equity interests of Chongqing Wintus Group, which is a private company based in China that produces specialized antiviral silk fabric materials that can be widely used in the medical, hygiene, pharmaceutical and personal health fields. According to the LOI, the total purchase price of the acquisition is estimated to be approximately $40 million which is expected to consist of cash and the Company's common stock. The LOI represents terms for a proposed transaction and will be subject to legal and financial due diligence, which includes a third-party audit and evaluation, Shineco's shareholder's approval and definitive documentation.

09:12 EST Apple unveils M2 Pro, M2 Max, two next-generation SoCs - Apple announced M2 Pro and M2 Max, two next-generation SoCs, systems on a chip, that take the breakthrough power-efficient performance of Apple silicon to new heights. M2 Pro scales up the architecture of M2 to deliver an up to 12-core CPU and up to 19-core GPU, together with up to 32GB of fast unified memory. M2 Max builds on the capabilities of M2 Pro, including an up to 38-core GPU, double the unified memory bandwidth, and up to 96GB of unified memory. "Only Apple is building SoCs like M2 Pro and M2 Max. They deliver incredible pro performance along with industry-leading power efficiency," said Johny Srouji, Apple's senior vice president of Hardware Technologies. "With an even more powerful CPU and GPU, support for a larger unified memory system, and an advanced media engine, M2 Pro and M2 Max represent astonishing advancements in Apple silicon."

09:11 EST FS Bancorp announces receipt of fegulatory approvals to Buy branches - FS Bancorp, the parent company of 1st Security Bank of Washington, announced that all required regulatory approvals had been received for 1st Security Bank to purchase seven branches from Columbia State Bank, a subsidiary of Columbia Banking System, in Washington and Oregon. The completion of the transaction remains subject to customary closing conditions and is expected to occur on February 27, the company noted.

09:10 EST ClearOne regains compliance with Nasdaq's minimum bid price requirement - ClearOne announced that it received a letter from Nasdaq on December 23, 2022, notifying ClearOne that, because ClearOne's stock has traded above $1.00 for 10 consecutive business days, ClearOne has regained compliance with Nasdaq Listing Rule 5550(a)(2). "We are pleased to regain compliance with Nasdaq Listing Rules and to begin 2023 with a record cash position of over $57 million. We look forward to beginning an exciting new chapter of the ClearOne story that is full of promise and opportunity. As a first step, we repaid the $2 million bridge loan that we borrowed in October 2022," said Derek Graham, ClearOne's Interim CEO. "After paying applicable taxes, we plan to use our cash to aggressively pursue revenue growth, eliminate debt, and reward our shareholders for their steadfast support of ClearOne through the difficult times we have faced in the past. We feel we have a bright future ahead of us," added Graham.

09:09 EST Innodata selected by 'leading' cloud infrastructure platform for data collection - Innodata announced it has been selected by a "leading cloud infrastructure and platform services company" to provide large-scale data collection for a new AI computer vision initiative. "In this latest win, Innodata will be responsible for collecting training data that is large-scale, high-quality and diverse. These are three key criteria for ensuring that AI performs well with real-world data," said Jack Abuhoff, Innodata CEO. Innodata anticipates the win will yield approximately $1M of revenue, the company noted.

09:08 EST Nuvei, Vtex announce global partnership agreement - Nuvei Corporation (NVEI) and VTEX (VTEX) announced a global partnership that will provide greater flexibility and customization for retailers as VTEX expands deeper into Latin America and new markets across Asia Pacific, North America and Europe. "Most companies today force brands to choose between customization or agility. At VTEX, we take a different approach. We deliver unprecedented time-to-revenue with an extensive set of capabilities. That is why this partnership is so strategic," said Santiago Naranjo, Chief Revenue Officer at VTEX. "From the outset, Nuvei understood our clients' needs and showed how to customize payments technology at speed with scale," Naranjo added.

09:07 EST Avalon issues 'key' U.S. patent for protein receptor molecules - The company states: "Avalon GloboCare announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,555,060, titled "QTY Fc Fusion Water Soluble Receptor Proteins." The issued claims cover the composition of matter and methodology for multiple novel QTY-code modified cytokine and chemokine protein receptor molecules. The patent was jointly filed with Dr. Shuguang Zhang of the Massachusetts Institute of Technology. The "QTY Code," is a breakthrough technology that can turn difficult to work with water-insoluble transmembrane receptor proteins into water-soluble proteins, greatly enhancing the solubility of designer peptides and proteins, therefore expanding the repertoire of selected therapeutic targets against cancers and other diseases."

09:07 EST Power Slap and Rumble expand global content partnership - Rumble, the video-sharing platform announced an expanded content partnership with Power Slap, the world's premier slap fighting organization. Rumble will become Power Slap's Official Digital Platform for the debut of its flagship television program Power Slap: Road to the Title globally in all countries outside of the United States, starting with the series premiere tomorrow.In addition to Dana White's "If You Don't Know" short form exclusive that will be posted exclusively to Rumble on Tuesdays starting today, Rumble users will also have exclusive access to After Slap, a recap show hosted by Dan Hellie and Charly Arnolt and featuring special guests. After Slap will debut in the United States on Wednesdays at 11:00 p.m. ET after each episode of Power Slap: Road to the Title.

09:07 EST AYRO, Masters Golf Carts announce partnership for AYRO Vanish - AYRO announced a partnership with Masters Golf and Utility Vehicles, a dealer and fleet solutions provider for the Ontario Province of Canada. "This new partnership is key for AYRO as it makes the AYRO Vanish available throughout Ontario and in nearby Toronto," said AYRO CEO Tom Wittenschlaeger. "Ontario has the largest population and largest opportunity for business applications for the AYRO Vanish in all of Canada. In addition the City of Toronto is seeking to transition its government fleet vehicles to electric, which also aligns with our product and vehicle offerings."

09:06 EST Varonis introduces least privilege automation - Varonis Systems announced a new milestone in cloud security with the release of least privilege automation for Microsoft 365, Google Drive, and Box - a new capability that continuously removes unnecessary data risk without human intervention. This innovation furthers Varonis' mission to deliver effortless data security outcomes to customers. Unlike other solutions that take an all-or-nothing approach, Varonis' cloud-native platform makes intelligent decisions about who needs access to data and who doesn't based on usage, data sensitivity, and exposure. Organizations can customize remediation policies to fit their security and compliance requirements, and least privilege automation continually enforces them without impacting collaboration.

09:06 EST Wish announces integrations with ShipStation and ShippingEasy - ContextLogic announced its partnership with two Auctane brands: ShipStation, the world's leading cloud-based ecommerce shipping solution, and ShippingEasy, the easy-to-use, cloud-based shipping, tracking, and customer marketing platform for ecommerce sellers. As part of the agreement, Wish merchants in the US, Canada, UK, Australia and New Zealand will gain access to both ShipStation and ShippingEasy fulfillment software. "We're always looking for ways to team up with best-in-class partners to provide more value for our global merchant base, while also positively impacting our consumer experience," said Mauricio Monico, Chief Merchant Officer, Product Management at Wish. "I am pleased that our merchants will benefit from access to significantly discounted shipping rates, as well as more resources and end-to-end support across every stage of fulfillment." "We aim to help our merchants make connections with new customer bases, and consumers increasingly want to shop on their phones. We're thrilled to offer our merchants access to the fast-growing mobile marketplace, in tandem with our leading ecommerce workflow capabilities," said Robert Gilbreath, General Manager of ShipStation.

09:05 EST DoorDash, Starbucks set to expand delivery partnership nationwide - Starbucks Coffee (SBUX) and DoorDash (DASH) announced the expansion of their partnership with new delivery service launching today in Northern California, Texas, Georgia, Florida and other select markets. Starbucks delivery via DoorDash will expand to additional markets over the coming months, with full nationwide availability anticipated in all 50 states by March 2023. This expansion follows on the heels of positive feedback from a successful pilot in Atlanta, Houston, and Sacramento, and additional market expansion in Seattle, Portland, and New York City last year. Through the partnership and as the largest local commerce platform in the country, DoorDash provides a delivery platform to enable increased, convenient access to Starbucks nationwide. "As customer behaviors evolve, we continue to innovate the Starbucks Experience to connect with them through meaningful and valuable digital experiences. Our partnership with DoorDash allows us to provide our customers with another convenient way to enjoy Starbucks wherever they are," said Brooke O'Berry, Starbucks senior vice president of digital experiences. "Delivery continues to be a significant growth opportunity for Starbucks, and we're excited to reach more customers by partnering with DoorDash, a company known for their best-in-class service."

09:04 EST Westhaven Gold announces drill results at Shovelnose Gold Property - Westhaven Gold announced drill results from its drill campaign at its 100% owned 17,623-hectare Shovelnose gold property. Shovelnose is located within the prospective Spences Bridge Gold Belt, which borders the Coquihalla Highway 30 kilometres south of Merritt, British Columbia. Westhaven is reporting assays for 22 holes from its drill campaign at Shovelnose. An additional 10 holes are in the lab pending assays. Gareth Thomas, President & CEO, comments: "We have now drilled greater than 450 gram-metre gold intercepts on three separate zones at Shovelnose gold property. This latest intercept at Franz, is 1km northwest from the hole at the FMN zone where we drilled the highest gold-silver intercept ever on the property at 857 gram-metres gold, and 2.3km from the 1.1-million-ounce gold equivalent resource at South Zone. The recent Franz drilling is significant because the mineralization starts at surface, is easily accessible, and bonanza grade. Hole SN22-333 was collared 50m from SN20-101 which was the best hole drilled at Franz until now. Drilling at the Franz will resume shortly with the view of stepping out to the northwest to test for the extension of this high-grade intercept." Recent Highlights: SN22-333 : Franz: 3.70 metres of 39.27 g/t gold and 55.81 g/t silver; 12.00m of 39.42 g/t Au and 51.81 g/t Ag, including 6.20m of 73.51 g/t Au and 92.37 g/t Ag. SN22-334 : Franz: 50.38m of 1.09 g/t Au and 6.37 g/t Ag, including 1.42m of 27.47 g/t Au and 119.40 g/t Ag. These recent Franz drill results are significant because, in conjunction with previous drilling, they demonstrate the subsurface continuity of bonanza grade mineralization extending from immediately beneath the exposed bedrock outcrop to a depth of about 60m. Next steps to establish a resource within this 165m long vein system, and to potentially facilitate the collection of a larger surface sample, would be additional shallow drilling, preliminary metallurgical test work and enhanced environmental baseline studies. Peter Fischl, Exploration Manager, comments: "Drilling continued through the Fall on Shovelnose, focusing on the FMN and Franz targets. A series of 50m spaced step-outs were completed on Vein Zone 1, tracing the zone northwestward to the Franz-FMN cross-fault. The zone and flanking rhyolite dykes are displaced by about 170m to the southwest, where they outcrop as the Franz showing. Drilling continued to Franz to confirm and better define higher grade mineralization at surface, immediately west of the cross-fault. This outcropping of Vein Zone 1 at Franz likely represents the uplift of the Franz block by tens of metres on the west side of the Franz-FMN cross-fault. The control of higher grades along Vein Zone 1 may in part be due to the presence of syn-mineral cross-structures, some of which may have been reactivated as post-mineral cross-faults, such as the Franz-FMN cross-fault. The higher grades encountered at Franz immediately west of the Franz-FMN cross-fault may be related to the intersection of Vein Zone 1 and this cross-structure. Vein Zone 1 is being reassessed for such structures, for example in the southeastern part of FMN towards the Tower Target, in an area of looser spaced drilling that may have missed such mineralization."

09:03 EST Cantaloupe appoints Novoseletsky as Chief Legal, Compliance Officer - Cantaloupe (CTLP) announced that Anna Novoseletsky has been appointed Chief Legal and Compliance Officer & General Counsel, Corporate Secretary effective January 17, 2023. Novoseletsky is a seasoned attorney with expertise in global payments, digitization, and e-commerce. She joins Cantaloupe from Discover Financial Services (DFS) where she was VP & Associate General Counsel, and Head of Legal.

09:02 EST AIM ImmunoTech in pancreatic cancer research pacts with AstraZeneca - AIM ImmunoTech (AIM) announced it has entered into an external sponsored collaborative clinical research agreement with Erasmus MC and AstraZeneca (AZN). Under the agreement, Erasmus MC is planning to perform an investigator-initiated clinical study, entitled "Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal adenocarcinoma for therapy effect. DURIPANC Study," in which it will use both Study Drugs provided by AstraZeneca and AIM ImmunoTech. "We have been diligently working to advance the development of Ampligen as a synergistic combination therapy with checkpoint inhibitors based on the promising data demonstrated to date. In the previously conducted human clinical studies, Ampligen has shown synergistic potential with PD-1 checkpoint blockade therapeutics. We are thrilled to take this important step forward in clinical development in collaboration with AstraZeneca and its PDL-1 therapy, durvalumab, and further unlock the potential of Ampligen for the treatment of pancreatic cancer where there remains significant unmet need," commented Thomas K. Equels, MS JD, Chief Executive Officer of AIM.

08:59 EST Atlis says investments in alternative fuels and hydrogen should be minimized - Atlis Motor Vehicles released the following statement after the Biden-Harris administration issued the first-ever U.S. National Blueprint for Transportation Decarbonization, developed by the US departments of Energy, Transportation, Housing and Urban Development, and the Environmental Protection Agency outlining plans to decarbonize transportation nationwide. Mark Hanchett, Atlis Motor Vehicles' Founder and CEO, said: "After reviewing the Blueprint, we believe investments in alternative fuels and hydrogen should be minimized, and more focus should be placed on proven technologies with tremendous growth potential. Additional resources should be concentrated toward funding companies in industries focused on the development of cleaner heavy equipment, especially for those in rural communities across America. The team at Atlis Motor Vehicles would be happy to discuss such innovative recommendations with officials, as Atlis is committed to increasing the nation's energy security, improving public health, and advancing the administration's clean transportation agenda." "The Government plays an important role in fostering environments in which businesses may thrive and develop cutting-edge solutions to push our nation forward in its quest to decarbonize and become energy independent. Hopefully, this blueprint will successfully drive attention and resources towards the advancement of new technology, though I believe this effort should be led from the private sector."

08:56 EST Transocean announces proposed private offering of $1.175B - Transocean announced that Transocean Inc., its wholly-owned subsidiary has commenced an offering of U.S. $1.175 billion aggregate principal amount of senior secured notes due 2030 to eligible purchasers pursuant to Rule 144A/Regulation S. The Notes will be fully and unconditionally guaranteed on a senior unsecured basis by Transocean Ltd. In addition, the Notes will be guaranteed on a senior secured basis by certain of Transocean Inc.'s subsidiaries that guarantee the existing 7.75% Senior Secured Notes due 2024 issued by Transocean Phoenix 2 Limited, 5.875% Senior Secured Notes due 2024 issued by Transocean Guardian Limited 6.25% Senior Secured Notes due 2024 issued by Transocean Proteus Limited and 6.125% Senior Secured Notes due 2025 issued by Transocean Pontus Limited, in each case, up to a secured guarantee cap equal to the principal amount of such notes being refinanced. Accordingly, Transocean Inc.'s subsidiaries that guarantee the Thalassa Notes, the Guardian Notes, the Proteus Notes and the Pontus Notes, will be subject to a Secured Limited Guarantee Cap on the Notes equal to $247 million, $320 million, $256 million and $352 million, respectively. The Notes will also be secured by a lien on Deepwater Thalassa, Deepwater Proteus, Transocean Enabler, Transocean Encourage and Deepwater Pontus and certain other assets related to the Collateral Rigs, up to the applicable Secured Limited Guarantee Cap.

08:55 EST One Stop Systems receives $3M AI compute order - One Stop Systems has received a $3 million dollar order from a prime military contractor to upgrade a radar simulation system operated by the U.S. Department of Defense Missile Defense Agency. The order includes deliveries of OSS 4UV compute accelerators systems, each powered by eight of the most powerful PCIe Gen4 Tensor Core GPUs available on the market today and using proprietary OSS Gen 4 PCI express-over-cable technology. The systems will be deployed in edge mobile radar systems and datacenters where they will be used for lab and field artificial intelligence training. OSS commenced system shipments in the fourth quarter of 2022, with remaining units to be delivered in the first half of 2023.

08:54 EST International Money Express appoints Christopher Hunt as COO - International Money Express announced several executive leadership changes effective immediately to support the Company's continued innovation and success. Christopher Hunt, who has served as Chief Information Officer of the company since March 2021, will move to the role of acting Chief Operating Officer. Chris will continue his oversight of technology for the business while adding product development, product operations, and facilities to his responsibilities. Chris' appointment will become permanent upon customary regulatory approval. Joseph Aguilar, who has served as Chief Operating Officer of the company since October 2019, will become President and General Manager - Latin America. In his new position, Joseph will be focused on all existing functions within Mexico and Guatemala, and in future Intermex operations in Latin America.

08:53 EST Silvergate Capital up 6% in pre-market trading at $14.00 after Q4 results

08:50 EST Canacol Energy announces share consolidation - Canacol Energy announced that, following shareholder approval of a consolidation of the common shares of the Corporation on the basis of five existing pre-consolidation Common Shares for every one post-consolidation Common Share at the special meeting of the shareholders of the Corporation held on December 19, 2022, it has filed articles of amendment implementing the Consolidation. The Common Shares will continue to be listed on the Toronto Stock Exchange under the symbol "CNE" and the Common Shares are expected to begin trading on a post-Consolidation basis on the TSX on or about January 20, 2023. Following the Consolidation, the new CUSIP number for the Common Shares is 134808302 and the new ISIN for the Common Shares is CA1348083025. In order to protect the interests of Canacol's shareholders holding their Common Shares through the Bolsa de Valores de Colombia and to avoid operational difficulties resulting from the Consolidation process, the BVC has decided to halt the trading of the Common Shares on the BVC starting on January 17, 2023. It is expected that trading of the Common Shares on the BVC will resume on a post-Consolidation basis on or about January 20, 2023. Trading of the Common Shares on the TSX will not be halted. As a result of the Consolidation, the 170,557,290 Common Shares issued and outstanding prior to the Consolidation have been reduced to approximately 34,111,458 Common Shares. Each shareholder's percentage ownership in the Corporation and proportional voting power remains unchanged after the Consolidation, except for minor changes and adjustments resulting from the treatment of any resulting fractional Common Shares.

08:50 EST Morgan Stanley says macro backdrop created challenges in 2022 - Expects C/C wealth and investment management business to become increasingly larger part of pre-tax profit going forward. Says "steadily building" fixed income franchise. Says capital position provides "enormous flexibility." Says has ~200 bps of excess capital over regulatory requirement of 13.3%. Targeting long term client assets of $10T. Comments taken from Q4 earnings conference call.

08:49 EST Grom Social's Curiosity Ink Media acquires stake in Hey Fuzzy Yellow! - Grom Social Enterprises announced that Curiosity Ink Media, Grom's original content generator and prolific storytelling division, has acquired an equity stake in Hey Fuzzy Yellow!, an emerging original musical series and franchise entertainment brand for preschoolers. In securing the stake, Curiosity and Grom are partnering with international global production and distribution powerhouse, Toon2Tango GmbH & Co. KG, to co-produce the franchise's centerpiece series. Hey Fuzzy Yellow!, created and developed by Mundefinedns Swanberg and Toon2Tango, expertly blends original music, comedy and edutainment curriculum for preschoolers, will pursue ancillary brand extensions that advance the show's goal of imparting important and accessible life lessons while encouraging critical thinking skills through exploration and play. Hey Fuzzy Yellow! has secured financing and programming commitments from several international broadcasters and is planned to enter production this year. Additionally, pre-sales for the property will continue in February, when the series will be offered to international program suppliers at the 2023 Kidscreen Summit conference in Miami, an annual gathering of global programming services and content producers.

08:48 EST Blue Water appoints Timothy Ramdeen to board of directors - Blue Water Vaccines announced the appointment of Timothy Ramdeen to its board of directors. Mr. Ramdeen has nearly a decade of experience in private equity and hedge fund investing, capital markets, and company formation. Since June 2022, Mr. Ramdeen has been founder and managing partner of Dharma Capital Advisors, an investment and advisory firm focused on early-stage private and public companies. From March 2021 to March 2022, Mr. Ramdeen was co-founder, chief investment officer, and portfolio manager at Sixth Borough Capital Management, a multi-stage, event-driven hedge fund focused on both private and public equities.

08:46 EST Navigator Holdings acquires second vessel under Greater Bay Gas JV - Navigator Holdings announced the second vessel acquisition under its 60/40 joint venture with Greater Bay Gas, previously announced on September 30, 2022. The Joint Venture announced the purchase of its first of five vessels on December 20, 2022. The vessel, renamed Navigator Solar, is a 17,000 cbm liquefied ethylene gas carrier, built in 2018 and was delivered on January 16, 2023. The remaining vessels expected to be purchased over the next 12 months by the Joint Venture are three 22,000 cbm, 2019-built ethylene carriers. As previously announced, all five vessels will continue to be commercially managed under the Luna Pool collaboration arrangement, and technical management will be provided by the third-party technical manager, PG Shipmanagement Pte. Ltd. of Singapore.

08:44 EST Imax reports $215M global box office for "Avatar: The Way of Water" - Imax announced that Disney/Lightstorm's "Avatar: The Way of Water" is now the third highest grossing IMAX release of all time with more than $215M in Imax global box office through Monday in its first full month of release. With several weeks to go in its IMAX engagement, the film stands as the highest grossing IMAX release of all time in 44 countries and territories worldwide. Imax has accounted for 11.2% of the film's global box office on only a fraction of total screens. Through Monday, "Avatar: The Way of Water" has earned $75.7M on Imax screens in North America - the third highest IMAX Domestic box office performance ever and continues to gain ground in China, where IMAX screens have earned $47.6M to date - good for 23% of the Chinese box office on only 1% of screens. "Avatar: The Way of Water" will continue to screen across IMAX locations in most global markets into February. Cameron and Disney/Lightstorm currently have three more films in the "Avatar" saga planned through 2028.

08:43 EST Neuronetics: Data confirms NeuroStar effective treatment for anxious depression - Neuronetics announced a new peer-reviewed publication in the Journal of Clinical Psychiatry, presenting real-world evidence of the efficacy of NeuroStar Advanced Therapy for adult patients who suffer concurrently from anxiety symptoms and major depressive disorder , also known as anxious depression...In my years of psychiatric practice, I have seen many depressed patients experiencing significant anxiety symptoms that can be debilitating," said Dr. Todd Hutton, M.D., Chief Medical Director at Southern California TMS Center. "These results are impressive because they further illustrate the mental health benefits that NeuroStar TMS can provide for many patients with psychiatric disorders like anxious depression. Having access to this large registry allows us to further the research and establish best practices for treating physicians."Neuronetics received FDA clearance to treat anxious depression with NeuroStar Advanced Therapy in July 2022.

08:42 EST Aclarion names George Frey as KOL surgeon advisor - Aclarion announced that George Frey MD, Founder of the Colorado Comprehensive Spine Institute, will advise the company as a key opinion leader. Dr. Frey is a renowned surgeon and inventor with dozens of US and worldwide patents in medical devices, technologies, and methods. Dr. Frey's experiences as a clinician and entrepreneur will provide valuable direction to Aclarion.

08:41 EST Nexstar announces newly-created advertising sales structure, leadership team - Nexstar Media Group announced a newly-created advertising sales structure and leadership team designed to drive ad sales across Nexstar's diversified media portfolio by further emphasizing its client-first approach, combined with a new data-driven, multi-platform focus. Todd Braverman, who joins Nexstar after a lengthy career in executive sales positions at Warner Media, has been named Executive Vice President/Head of National Sales, responsible for driving top-line sales performance by identifying go-to-market sales strategies for agencies, clients, and audiences. Brad Epperson, who previously served as Senior Vice President/Business Operations and Services for NBCUniversal, has been appointed Executive Vice President/Platform Operations & Technology and will lead ad operations, including campaign management, targeting, delivery and optimization. Lori Tavoularis has been appointed Chief Business Officer after serving as Nexstar Digital's Chief Revenue Officer/Executive Vice President, Revenue Operations since 2021.

08:39 EST Aeterna Zentaris expects cash to fund operations into 2025 - "Our disciplined development strategy ensures that we establish progress in our projects within a defined timeframe, in order to optimize the Company's capital and human resources," said Giuliano La Fratta, Chief Financial Officer, Aeterna. "We continue to drive progress across a number of our programs and remain focused on advancing those programs to their next phase of development if we determine that the data and financial risk/reward of doing so is justified. The strategic decision to streamline our pipeline, by discontinuing our vaccine development, provides the Company with the ability to meet its currently anticipated cash needs into 2025. Revenues that may be achieved if we out-license any of those development programs are not considered in our budget and thus provides further upside potential."

08:39 EST PetMed Express to acquire PetCareRx, terms undisclosed - PetMed Express has reached a definitive agreement to acquire PetCareRx, a supplier of pet medications, food, and supplies.The combined entities will expand PetMeds' existing base of over two million customers and will add approximately 10,000 incremental wellness products to the company's existing product offering. The acquisition of PetCareRx gives PetMeds an immediate revenue boost, and the company believes it can expand on that growth through an expanded product catalog and differentiated services."We believe this acquisition will not only be highly beneficial to our customers but will also drive significant shareholder value over the long-term," said Matt Hulett, CEO and President of PetMeds. "Together, PetMeds and PetCareRx will provide a much expanded product offering and accelerated growth by capturing a larger share of customer wallet through increased basket size and order frequency within the booming $120B annual sales U.S. pet care market. Pet parents will benefit from expanded choice in both prescription and non-prescription medicines, and thousands of incremental products, including premium and prescription food, treats, and supplement. The transaction is subject to customary closing conditions and completion of regulatory review. The deal has been approved by the board of directors of both PetMeds and PetCareRx and is expected to close in the first quarter of 2023.

08:38 EST Color Star Technology cooperating with short video platform Detok - Color Star Technology subsidiary Color Metaverse has entered into a strategic cooperation framework agreement with short-video sharing platform, Le Shua - Detok -. The parties plan to help each other develop grow in their respective markets, increasing its range of support for various in-app content, thereby increasing Detok's global influence and user base. Detok is a blockchain-based short-video and live streaming platform. Detok's main principle revolves around the direct exchange of value between creators, viewers, and advertisers, combining short videos and live streaming with blockchain technology to create blockchain-based digital copyright protection. This makes it possible to administer and distribute copyrights. Color Metaverse plans to fully utilize all of Detok's existing resources, and provide the platform with a constant stream of new content including NFTs, new celebrity IPs, and digital features, in order to attract new users to browse the app's contents, generating more profit for its content creators.

08:37 EST Mawson Infrastructure produces 261.83 bitcoin in December - James Manning, CEO commented, "December was a record month for Mawson's energy market revenue, at approximately $4 million. This brought our equivalent BTC production to approximately 261.83 for the month, or 8.44 per day.1 This is approximately equivalent to the BTC revenue that could have been produced by 2.2 Exahash of mining in the month of December. This additional source of revenue has given Mawson an advantage through the past 6 months. Through the last 6 months this program has delivered unaudited revenue of $13.9 million. Our expansion at the Midland, Pennsylvania site continues to move forward at speed, with an online date still within Q1, 2023. The first MDCs have been delivered to our Sharon, Pennsylvania site, and we look forward to communicating the online date with our shareholders in the near future. Combined, these first containers have a total capacity of up to approximately 12 MW.2"

08:36 EST Aeterna Zentaris discontinues vaccine development pipeline - Orally active, live-attenuated bacterial vaccine platform with potential application against coronavirus, including COVID-19 and Chlamydia: The Company worked on evaluating administration routes, dosing and immunization scheme, and conducted in-vivo immunology experiments with candidate strains expressing various antigens in relevant mice models. To date, the Company has not been able to select a clinical development candidate for a COVID-19 vaccine. Also, COVID-19 vaccine landscape has continued to evolve profoundly in the past two years. There are highly effective vaccines available, an increasing number of therapeutic options are meanwhile approved or in later stage development and less lethal virus variants are spreading, all of which increase the financial risk associated with any early stage COVID-19 vaccine program. In order to ensure we are prudent with the use of resources, given the early stage of the Company's vaccine development programs and the changes in the global situation, Aeterna has decided that it will not pursue further development of the vaccine platform for either COVID-19 or Chlamydia, As a result, the Company has also elected to terminate its existing license agreements with the University of Wuerzburg for that vaccine platform technology.

08:35 EST Roblox reports December DAU 61.5M, up 18% - Roblox Corporation released certain key metrics for the month of December 2022. December 2022 Key Metrics: Hours engaged were 4.7 billion, up 21% year-over-year; Estimated revenue was between $189 million and $199 million, a decline of between 1% - 6% year-over-year.; Estimated bookings were between $430 million and $439 million, up 17% - 20% year-over-year; Estimated average bookings per daily active user were between $6.99 and $7.14, which represents a year-over-year change of -1% - +1%.

08:35 EST Aeterna Zentaris provides business update, upcoming milestones - Aeterna Zentaris provided a business update and outlined upcoming key milestones. "We have made significant development progress since we initiated six pre-clinical development programs in 2021," said Dr. Klaus Paulini, Chief Executive Officer of Aeterna. "We have established a growing body of data towards our pre-defined go/no-go decision points with the goal of enabling us to identify and select from those programs the most compelling opportunities that warrant continued development. We believe that we have built the foundation for continued momentum and are very encouraged with the disciplined progress we have made thus far." Diagnostics Development and Commercialization Update: Macimorelin Diagnostic: Approved and commercialized as test for adult growth hormone deficiency and in clinical phase 3 development for childhood-onset growth hormone deficiency testing: Aeterna is currently conducting its pivotal Phase 3 safety and efficacy study AEZS-130-P02 evaluating macimorelin for the diagnosis of Childhood Onset Growth Hormone Deficiency. Most clinical sites in the U.S. as well as European countries are open for patient recruitment. Recent Highlights: Phase 3 Study: Bolstered enrollment expected by the replacement of inactive countries/sites and engagement of an additional Clinical Research Organization. Currently four new countries, have ongoing DETECT clinical trial application activities. Macimorelin Commercialization: Having announced that Aeterna Zentaris will regain full rights to Macrilen for the U.S. and Canada from Novo Nordisk in May 2023, the Company is progressing its efforts to seek an alternate development and commercialization partner for Macrilen in those countries for continued commercialization of Macrilen in adult growth hormone deficiency and development and commercialization of Macrilen in CGHD. Achieved regulatory approval for Macrilen as AGHD diagnostic product in Israel. Next Steps and Expectations: Achieve approvals to conduct the DETECT trial in the new countries in the first half of 2023. Complete DETECT enrollment by the end of 2023. Continue efforts to secure a U.S. and Canadian development and commercialization partner for Macrilen in AGHD and CGHD. Achieve regulatory approval for Macrilen as AGHD-diagnostic in South Korea, Turkey and some non-EU Balkan countries

08:32 EST Xchange Benefits launches Xchange Re Underwriting Agency - Xchange Benefits, a managing general underwriter owned by Ambac Financial Group, announced it has launched a reinsurance MGU, Xchange Re Underwriting Agency. The new entity, which is a wholly owned subsidiary of Xchange Benefits, specializes in personal accident catastrophe and special risk reinsurance and retrocession. Xchange Re has signed a reinsurance underwriting management agreement with United States Fire Insurance Company, which operates under the registered trademark of Crum & Forster and has an AM Best rating of A. Xchange Re will underwrite worldwide accident and health reinsurance coverage, both non-proportional treaty and facultative/direct excess of loss business, on behalf of U.S. Fire. "We are thrilled to build upon our wide and longstanding relationship with Crum & Forster," said Peter McGuire, CEO of Xchange Benefits. "We have seen a great deal of disruption in the reinsurance market over the past year. We believe that this is an excellent time to enter this marketplace, and we have established Xchange Re to provide quality underwriting solutions to the accident and health industry.

08:30 EST ChromaDex announces findings from study on proprietary Niagen ingredient - ChromaDex announced promising findings from a first-of-its kind five-month-long clinical study, as reported in the peer-reviewed journal Science Advances by a team of scientists led by Dr. Eija Pirinen and Dr. Kirsi Pietilainen. The clinical trial was part of the ChromaDex External Research Program and investigated the company's proprietary Niagen ingredient in 20 BMI-discordant identical twin pairs. Results of the study showcase that Nicotinamide Riboside, NR, supplementation improved muscle mitochondrial biogenesis, satellite cell differentiation and gut microbiota composition. This is the first published and peer-reviewed clinical study demonstrating an increase in mitochondrial biogenesis following NR supplementation in humans and is consistent with a CERP preclinical study published in Cell Reports, demonstrating NR increased mitochondrial biogenesis in neuronal cells. Additionally at five months, this clinical study marks a milestone as the longest published NR supplementation study to date. "While previous preclinical research has demonstrated that increasing NAD+ through precursor supplementation improves the quality and quantity of muscle stem cells, promotes muscle function, increases mitochondrial health and respiration, and has therapeutic effects in mitochondrial and muscle disorders, many of these benefits have yet to be translated in human clinical studies," said Dr. Andrew Shao, ChromaDex Senior Vice President of Global Scientific & Regulatory Affairs. "This study marks an important milestone in research between NR supplementation and mitochondrial biogenesis."

08:29 EST Microchip launches first COTS rad-tolerant power device - Microchip Technology announces the introduction of its first commercial-off-the-shelf rad-tolerant power device with the MIC69303RT 3A Low-Dropout Voltage Regulator. The new high-current, low-voltage MIC69303RT is a power management solution targeting LEO and other space applications. The device is available for prototype sampling in both plastic and hermetic ceramic to support the requirements of the mission. The MIC69303RT is based on proven COTS devices, making it easier to conduct preliminary evaluation and early development. Operating from a single low-voltage supply of 1.65 to 5.5 volts, the device can supply output voltages as low as 0.5V at high currents, offering high-precision and ultra-low dropout voltages of 500 mV under extreme conditions. The MIC69303RT is a companion power source solution for Microchip's radiation-tolerant space-qualified microcontrollers such as the SAM71Q21RT and PolarFire FPGAs including the RTPF500TLS.

08:27 EST Rio Tinto guides 2023 Pilbara iron ore shipments 320-335 Mt vs. 322 in 2022 - Guides 2023 Bauxite shipments 54-57 Mt vs 55 Mt in 2022. Guides 2023 Alumina shipments 7.7-8.0 Mt vs 7.5 Mt in 2022. Guides 2023 Mined Copper shipments 650-710 kt vs 521 kt in 2022.

08:26 EST Spectair to go public via business combination with Perception Capital - Spectaire announced entry into a definitive agreement to go public via a business combination with Perception Capital Corp. II. Spectaire's products are intended to immediately help customers lower carbon offset payments, increase fleet activity efficiency and generate new revenue streams from carbon credits. Going forward, Spectaire's growing proprietary emissions database - comprised of actual emissions of mobile assets across different logistics channels - is expected to provide valuable data for customers to continuously and cost effectively improve the efficiency of customers' logistics networks. "Our technology is a win for our customers, our investors and the planet. Improving air quality is the single greatest challenge of this century and companies are under increasing pressure to account for - and reduce - their carbon footprints. They need tools to accurately track and report emissions in real time, and to reduce emissions, we must first accurately measure emissions. This is especially true in logistics, where an infinite number of variables change truck emission profiles minute-to-minute, mile-to-mile. Our MMS device is expected to give our customers a significant competitive edge by helping them lower costs, improve logistics network efficiency and access carbon credit revenues. I look forward to working with the Perception team to expand and accelerate production, thus bringing our MMS technology to more customers," said Brian Semkiw, Chief Executive Officer of Spectaire. The parties expect that the proposed Transaction will allow Spectaire to expand production of its emissions measurement and monitoring solution, meeting strong demand from existing and future customers. The proposed Transaction values Spectaire at a pro forma enterprise valuation of approximately $203M. The Boards of Directors of Perception and Spectaire have both unanimously approved the proposed Transaction. The proposed Transaction has also been approved by the requisite stockholders of Spectaire. Completion of the transaction is subject to customary closing conditions, including the approval of Perception's shareholders. The parties expect the proposed Transaction to close in the second quarter of 2023.

08:24 EST NewAmsterdam announces results from obicetrapib /ezetimibe combo trial - NewAmsterdam Pharma announced topline results from ROSE2, a Phase 2 clinical trial evaluating obicetrapib, the company's oral, low-dose and once-daily cholesteryl ester transfer protein inhibitor, in combination with ezetimibe as an adjunct to high-intensity statin therapy. Based on the encouraging results observed, NewAmsterdam is now selecting a formulated fixed-dose combination tablet of obicetrapib plus ezetimibe, a non-statin oral LDL-lowering therapy, to be tested in a definitive bioequivalence trial and a Phase 3 safety and efficacy trial."Elevated levels of LDL cholesterol remain a significant public health burden despite the availability of statins. While a range of adjunctive treatments are available, many patients are not able to benefit because these agents either do not sufficiently lower LDL-C or are too expensive," said Christie Ballantyne, M.D., Chief of Cardiovascular Research and Professor at Baylor College of Medicine. "Today, patients - especially those at high-risk - are typically treated with very high-dose statin therapy, which can be associated with intolerable side effects that limit adherence. Combination regimens comprising low-dose statin therapy plus another LDL-C lowering agent, such as a fixed-dose combination of obicetrapib and ezetimibe, may become a powerful strategy to deliver patients better outcomes, while also increasing their willingness and ability to remain on therapy."

08:24 EST SAIC receives $112M contract to deliver cloud based command, control - Science Applications International has been awarded a $112M contract to develop Cloud Based Command and Control, CBC2, for the U.S. Air Force Advanced Battle Management System, ABMS. "SAIC is passionate about applying technology and innovation to the future battlespace," said Michael LaRouche, president, National Security and Space sector at SAIC. "We are excited to be selected for this program to help modernize command and control systems and enable the DoD's Joint All Domain Command and Control vision. We are dedicated to advancing ABMS as a strategic partner to the Air Force."

08:23 EST Natera announces publication of new study on ability of Signatera test - Natera announced the publication of a new study in Nature Medicine, which demonstrates the ability of the Signatera molecular residual disease, MRD, test to identify patients with stage II-IV colorectal cancer, CRC, who are at an increased risk of recurrence and predict who is likely to benefit from adjuvant chemotherapy, ACT. With this study, data supporting the clinical validity and utility of Signatera has now been published in 40 peer-reviewed publications. In the study, 1,039 patients with stage II-IV resectable CRC were monitored prospectively using the Signatera MRD test. Key takeaways include: Post-surgical MRD status was predictive of chemotherapy benefit. Patients who were MRD-positive four weeks after surgery derived significant benefit from ACT. MRD-negative patients did not see a significant benefit from ACT. Post-surgical MRD status was the most significant prognostic risk factor for recurrence, in a multivariate analysis that accounted for all clinicopathological risk factors currently used for prognostication. Pre-surgical detection rate of 95.9% in patients with pathologic stage II-III disease and 93.1% in patients with stage II-IV disease. Signatera dynamics are indicative of treatment response. Among the MRD-positive patients who were treated with ACT, those with ctDNA clearance had superior DFS compared to those without ctDNA clearance. "This is a practice-changing study for the colorectal cancer community, demonstrating the predictive power of Signatera in the adjuvant setting," said Minetta Liu, M.D., chief medical officer of oncology at Natera. "We are proud to partner with the CIRCULATE consortium and look forward to making Signatera accessible to all colorectal cancer patients in the U.S., Japan and worldwide."

08:21 EST Frontier appoints Newmark to manage its real-estate portfolio - Frontier (FYBR) announced it appointed Newmark (NMRK) to manage its real-estate portfolio. Newmark's leading-edge, real-estate technology platform, Newlitic, and market expertise will help Frontier further streamline operations and identify cost savings opportunities. "As we advance our purpose of Building Gigabit America, simplifying our real-estate portfolio represents an important opportunity to reduce our cost structure and improve the sustainability of our footprint," said Scott Beasley, Frontier's Chief Financial Officer. "We're excited to partner with Newmark to use their technology and experience to accelerate our real-estate transformation."

08:20 EST GAP Airports guides FY23 revenue up 12%-14% - Grupo Aeroportuario del Pacifico announced its guidance for the full year 2023 compared to 2022, forecasting traffic up 6%-8%, Aeronautical Revenue up 12% - 14%, Non-aeronautical Revenue up 13% - 15%, Total Revenue up 12% - 14%, EBITDA up 10%-12%, EBITDA Margin 69%-71%, and CAPEX around MXN 10.2B.

08:20 EST Taboola and Yahoo close previously announced strategic pact - Yahoo and Taboola announced they have closed their previously announced 30-year exclusive commercial agreement. This unique deal makes Taboola the exclusive native advertising partner for all of Yahoo's digital properties, strengthening Taboola's position as a leading native advertising offering for advertisers, publishers and merchants on the open web. The partnership brings Taboola to Yahoo's iconic digital properties, which reach nearly 900 million monthly active users worldwide across mail, sports, finance and news. Coupled with Taboola's reach among 9,000+ publisher partners and 500M active users a day, this deal gives brands massive scale to reach consumers in Yahoo's trusted editorial environments, while also providing greater contextual data to reach consumers. Under the partnership, Yahoo also enhances its unified advertiser offerings, improves consumer experiences across its owned media properties, and benefits from shared value creation as Taboola's largest shareholder. As part of the deal, Monica Mijaleski, CFO at Yahoo, has joined Taboola's Board of Directors. This partnership offers immense benefit for publishers working with Taboola in terms of revenue, engagement and audiences. Through combined demand of Yahoo and Taboola, publishers, including Yahoo's owned and operated properties will get more premium advertisers bidding on the Taboola network, increasing quality and yields automatically. The collaboration will also develop new contextual segments for advertisers so that as they find it harder to buy on social networks, they can rely on Taboola to make them successful, which will also increase yield.

08:19 EST ShockWave Medical to acquire Neovasc for $27.25 per share - Neovasc (NVCN) announced that the Company has entered into a binding agreement with Shockwave Medical (SWAV), whereby Shockwave has agreed to acquire all of the issued and outstanding common shares of the Company. Under the terms of the Arrangement Agreement, Neovasc shareholders will receive US$27.25 per Common Share in cash upfront on completion of the Transaction, corresponding to an enterprise value of approximately US$100 million, plus deferred payments of up to approximately US$47 million on the achievement of future regulatory milestones in the form of a contingent value right per Common Share to receive payment upon final FDA premarket approval to market the Neovasc Reducer in the United States for treatment of angina. Each CVR will pay: US$12.00 if the Milestone is achieved on or prior to June 30, 2026, US$8.00 if the Milestone is achieved during the period beginning on July 1, 2026 and ending on December 31, 2026 or US$4.00 if the Milestone is achieved during the period beginning on January 1, 2027 and ending on December 31, 2027. The upfront cash consideration represents a premium of 27% and 68% to the closing price and 30-day volume-weighted average price respectively, of the Common Shares on the Nasdaq Capital Market on January 13, 2023. The Transaction will be implemented by way of a court-approved plan of arrangement under the Canada Business Corporations Act and will require approval of at least 66 2/3% of the votes cast by the holders of Common Shares; and approval by such holders excluding Common Shares held by certain "interested parties" in accordance with Multilateral Instrument 61-101, at a special meeting of Company shareholders to be held to consider the Transaction. In addition to approval by Company shareholders, the Transaction is also subject to receipt of court approval, and other customary conditions for transactions of this nature. The Transaction is expected to be complete in the first half of 2023. The Arrangement Agreement provides for customary deal-protection provisions, including a non-solicitation covenant on the part of the Company and a right for Shockwave to match any Superior Proposal. The Arrangement Agreement includes a termination fee of US$3.824 million, payable by the Company under certain circumstances. The directors and senior officers of the Company and Strul Medical Group, owning in aggregate approximately 9.23% of the Company's voting securities, have entered into voting support agreements, pursuant to which they have agreed to vote all of the securities they own or control in favour of the Transaction. Pursuant to Strul's voting and support agreement, Strul has also agreed, among other things, to convert into Common Shares at the conversion price of US$25.00, the Restated Senior Secured Convertible Note issued by the Company to Strul with an initial principal amount of US$13,000,000, immediately prior to the effective time of the Transaction, that it shall be entitled to exercise its right to have the Company purchase certain warrants to acquire Common Shares held by Strul for a cash amount equal to the value thereof, and that certain out of the money warrants to acquire Common Shares held by Strul shall terminate at the effective time of the Transaction. A special committee comprised entirely of independent directors of the Company and advised by its financial advisor and by counsel unanimously recommended entering into the Arrangement Agreement to the board of directors of Neovasc. The Board has evaluated the Arrangement Agreement with the Company's management, legal and financial advisors and, following the receipt and review of the unanimous recommendation from the Special Committee, the Board has unanimously approved the Transaction and determined that the Transaction is in the best interest of the Company. The Board has resolved to recommend that the Company's shareholders vote in favour of the Transaction, all subject to the terms and conditions contained in the Arrangement Agreement.

08:18 EST BigCommerce announces launch of MKM's new online storefront - BigCommerce announced the launch of MKM Building Supplies' new online storefront. Built with powerful headless technology on the back end to enable scalability and flexibility, the new site delivers a unified omnichannel and seamless B2C shopping experience to drive sales. "MKM's unique business model, continued company growth and desire to serve our diverse range of customers with exceptional and hyper-personalized shopping experiences meant we had to revitalize our online store and evolve in an increasingly digital world," said Andy Pickup, digital & marketing director at MKM Building Supplies. "Launching on BigCommerce allowed us to personalize the customer journey and deliver frictionless experiences across channels. Since moving to the platform, we have been performing above expectations on ecommerce metrics and driving more physical store visits."

08:16 EST Theriva Biologics announces 1st patient dosed in VIRAGE Phase 2b trial - Theriva Biologics announced the first patient has been dosed in VIRAGE, the Phase 2b randomized, open-label, placebo-controlled, multicenter clinical trial of systemically administered VCN-01 in combination with standard-of-care SoC chemotherapy or gemcitabine/nab-paclitaxel as a first line therapy for patients with newly-diagnosed metastatic pancreatic ductal adenocarcinoma, PDAC."The dosing of the first patient in our Phase 2b PDAC trial represents an important step in our pursuit to address unmet needs for patients with difficult-to-treat cancers," said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics. "The incidence of PDAC continues to rise and while it continues to have one of the lowest survival rates among all cancer types, efforts to improve upon the standard of care treatment have largely stalled. In contrast, we are encouraged by the growing clinical data that underscore VCN-01's differentiated mechanism of action, as well as the biological activity and synergistic clinical benefit observed in combination with SoC chemotherapy for patients with PDAC and other solid tumors. With regulatory clearance from the FDA and AEMPS, we look forward to the continued progress of this program and more broadly, the advancement of our novel OV platform."

08:15 EST SuRo Capital estimates net asset value $7.15-$7.65 per share as of Dec. 31 - SuRo Capital provided the following preliminary update on its investment portfolio for the fourth quarter and fiscal year ended December 31, 2022. "2022 has been well documented as one of the worst years for equity markets in decades. However, as we move into the new year with approximately $125 million of investable capital, we stand ready to continue investing in both primary and secondary opportunities for later-stage, high-growth companies at what we believe will be compelling valuations. To that end, during the fourth quarter of 2022, we completed a $10 million primary investment in Locus Robotics Corp., a leader in autonomous mobile robots for fulfillment and distribution warehouses," said Mark Klein, Chairman and Chief Executive Officer of SuRo Capital. "Based on information presently available, for the quarter and year ended December 31, 2022, we anticipate SuRo Capital's net asset value to be approximately $7.15 to $7.65 per share."

08:14 EST Angion Biomedica, Elicio Therapeutics enter into merger agreement - Elicio Therapeutics has entered into a definitive merger agreement with Angion Biomedica under which Elicio will merge with a wholly-owned subsidiary of Angion in an all-stock transaction. The combined company will continue under the Elicio Therapeutics name and will focus on advancing Elicio's proprietary lymph node-targeting Amphiphile technology to develop immunotherapies, with a focus on ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors. Under the terms of the merger agreement, pending stockholder approval of the transaction, Elicio will merge with a wholly-owned subsidiary of Angion, and stockholders of Elicio will receive newly issued shares of Angion common stock. Current Angion stockholders are expected to own approximately 34.5% of the newly combined company while Elicio stockholders will own 65.5% of the newly combined company, in each case on a fully diluted basis. The final percentage of the combined company owned by Elicio stockholders and Angion stockholders upon completion of the merger may be subject to certain adjustments, including potential adjustments based on Angion's net cash balance upon deal completion. The proposed transaction has been unanimously approved by the boards of directors of both companies and is expected to close in the second quarter of 2023, subject to customary closing conditions. Concurrent with the execution of the merger agreement, Angion committed up to $10 million in a bridge loan to Elicio, to be made in two installments, subject to certain conditions.

08:13 EST Crowdstrike adds two executives to its leadership team - CrowdStrike (CRWD) announced that two key executives have joined its leadership team. Daniel Bernard has been appointed as chief business officer, and Raj Rajamani has been named chief product officer, DICE. Bernard will report directly to CrowdStrike founder and CEO, George Kurtz. Rajamani will report to CrowdStrike's chief product & engineering officer, Amol Kulkarni. Bernard and Rajamani, who most recently served as the chief marketing officer and chief product officer at SentinelOne (S), respectively, bring experience with high-growth, disruptive cloud and SaaS businesses.

08:12 EST LSU deploys Infinera XTM and GX series to upgrade LONI - Infinera announced that the Louisiana Board of Regents, acting on behalf of the statewide Louisiana Optical Network Infrastructure and the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, has selected and deployed Infinera's advanced coherent optical networking solutions to upgrade LONI. Also announced is the initial deployment of four 400G optical channels along a 220-mile intrastate route in Louisiana. LONI connects 38 university campuses and data centers and provides connectivity to additional research and education networks in other states. The solution, which increases LONI's network capacity by a factor of 10, comprises Infinera's XTM Series open line system and GX Series transponders. The upgraded network expands the ability for the research and education community to share and access information, resources, and remote instruments in real time.

08:11 EST SPX Technologies announces sustainability commitments - SPX Technologies announced its sustainability commitments. The company has committed to a 30% reduction in greenhouse gas emissions intensity by 2030, and greater transparency in our diversity and inclusion disclosures, as we focus on enhancing our performance annually.

08:10 EST DatChat launches live video chat application with anti-screenshot protection - DatChat released their live encrypted video chat application with screenshot and screen capture protection as part of the DatChat Messenger. The new feature allows DatChat users to connect via an encrypted live video chat that also is designed to prevent screenshots or screen grabs. As of today, the video chat application is available as part of The DatChat Social Network+ app, available as a free download for iOS and Android.

08:08 EST Delcath Systems reports updated results from Phase 1b melanoma trial - Delcath Systems announced the publication of updated results from the Phase 1b CHOPIN Trial on the use of the Delcath Chemosat Hepatic Delivery System with Melphalan in combination with the immune checkpoint inhibitors ipilimumab and nivolumab to treat patients with metastatic uveal melanoma with liver metastases. The goal of the CHOPIN trial is to study the safety and potential synergistic effects of systemic ICI therapy ipilimumab plus nivolumab when combined with Delcath's proprietary liver-targeted percutaneous hepatic perfusion treatment in metastatic uveal melanoma patients. The Phase 1b portion of the trial enrolled seven patients each of which were treated with two courses of PHP combined with four courses IPI+NIVO. As previously reported, the Best Overall Response included 1 complete response, 5 partial responses and 1 stable disease accounting for an Objective Response Rate of 85.7% and a Disease Control Rate of 100%. All patients are still alive and three of four patients who subsequently experienced PD continued with treatment in the form of repeated melphalan PHP cycles. Grade 1/2 adverse events were seen in all patients and 71.4% experienced grade 3/4 toxicities. In this phase 1b dose-escalation study combining M-PHP with IPI/NIVO the safe treatment dose was established at IPI 1mg/kg and NIVO 3mg/kg. The phase 2 part of the CHOPIN study will provide more information on both hepatic and systemic toxicity associated with the combination therapy.

08:08 EST PLBY Group and Charactopia announce Playboy China joint venture - PLBY Group announced that they have entered into a shareholders agreement to form "Playboy China", a joint venture that will jointly own and operate the Playboy branded consumer products business in parts of the China market, including mainland China. The Playboy China joint venture will focus on reinvigorating all aspects of the China-market Playboy apparel business, including online and offline retail strategies, product design and assortment, and brand marketing to its multi-generational audience. The Shanghai-based joint venture team will look to build on Playboy's current roster of licensees and online storefronts by adding new partners and growing through new product categories yet to be developed in China with the Playboy brand.The joint venture will be governed by a Board of Directors that includes representatives from both Playboy and Charactopia with Playboy retaining majority ownership of the Playboy China joint venture, which is valued by the partners at US$250 million. The Playboy China joint venture team will work closely with the Playboy apparel team in the U.S. to ensure a unified presentation and positioning for the Playboy brand globally.

08:07 EST Critical Metals announces MoU between European Lithium, Obeikan - European Lithium, a mineral exploration company in a proposed business combination with Sizzle Acquisition Corp to form Critical Metals Corp, announced it has signed a non-binding Memorandum of Understanding, MoU, with Obeikan Investment Group to build and operate a hydroxide plant in Saudi Arabia for the Wolfsberg Lithium Project in Austria. Under the MoU, which would create a joint venture between the two parties, European Lithium and Obeikan will work together to negotiate suitable commercial terms for the construction and operation of a hydroxide plant in Saudi Arabia, although no assurance is given that a binding agreement will be executed. Critical Metals Executive Chairman Tony Sage commented: "This proposed JV with Obeikan will unlock key opportunities for Critical Metals. It will allow us to focus our efforts on building the facilities to start mining concentrate, and is expected to result in significant energy cost savings for the Wolfsberg Project."

08:05 EST Braskem announces project to evaluate production of bio-based polypropylene - Braskem announced a project to evaluate an investment in producing carbon negative bio-based polypropylene in the U.S. The project would utilize Braskem's proven, proprietary technology to convert bioethanol into physically segregated bio-based polypropylene. Braskem is exploring partnership opportunities for this project with several clients, brand owners, and suppliers. Mark Nikolich, Braskem America CEO, commented, "Building on our core technology and market leadership, we are actively evaluating a project to produce the world's first bio-based polypropylene on an industrial scale to support our ambitious sustainability objectives and deliver tangible solutions to our clients. As an established leader in the innovation and production of bio-based materials, we have seen the demand for Braskem's bio-based materials grow significantly since our initial product launches. This new U.S.-based project would not only serve a growing market for sustainable solutions but also reduce Braskem's reliance on fossil feedstock. Expanding our portfolio to include bio-based PP supports Braskem's goal of 1MM tons of biopolymers capacity by 2030 and becoming carbon neutral by 2050."

08:05 EST Rolls-Royce, Xanadu to co-develop quantum computing tools with PennyLane - Xanadu and Rolls-Royce are co-developing new quantum algorithm tooling for PennyLane, Xanadu's open-source quantum computing software widely used for quantum machine learning, chemistry, and optimization. Xanadu and Rolls-Royce are committed to advancing the field of quantum computing, studying its potential to solve complex problems and building tools with lasting business impact. The first project will develop quantum software functionality tailored for Quantum Singular Value Transformation, or QSVT, in PennyLane to help Rolls-Royce accelerate its research into quantum algorithms for aerospace applications. QSVT is a modern paradigm for quantum algorithms that enables innovative methods for employing quantum computers to explore a variety of problems of interest.

08:04 EST GrowGeneration announces new store in Traverse City, Michigan - GrowGeneration announced the acquisition of inventory and equipment from The Grow Store, a family owned and operated business located in Traverse City, Michigan, with roots dating back to 1997 as one of the first hydroponics and indoor garden centers in the country. As a part of the transaction, GrowGen also took over the existing store location at 90 N. US-31 S., Traverse City, MI. Darren Lampert, Co-Founder and Chief Executive Officer of GrowGen said, "We are excited to expand our retail footprint to northern Michigan to more efficiently and effectively service the many growers in that area. The Grow Store has had incredible success and we are excited to continue its legacy in the Traverse City market."

08:03 EST ShockWave Medical to acquire Neovasc for $27.25 per share

08:02 EST Skeena Resources announces signing of Eskay Creek process charter - Skeena Resources announces the signing of the permitting Process Charter and other key milestones in the approval process for the Eskay Creek gold-silver Project located in Tahltan Territory in the Golden Triangle of British Columbia. The Process Charter is a unique collaboration between Skeena, the Tahltan Central Government, and the Government of BC. This document establishes a workplan for all parties to collaborate on an efficient Environmental Assessment and permitting process for Eskay Creek. The target timelines established in the Process Charter outline the EA Certificate being received in H2 2024 and final permits to be issued in H1 2025. These dates align with the development timeline anticipated for the Project.

08:01 EST Leap Therapeutics acquires Flame Biosciences - Leap Therapeutics and Flame Biosciences, a privately-held biotechnology company, have entered into a definitive merger agreement pursuant to which Leap has acquired Flame and its assets, including FL-301, its clinical stage anti-Claudin18.2 monoclonal antibody, FL-302, its preclinical anti-Claudin18.2/CD137 bispecific monoclonal antibody, FL-501, its preclinical anti-GDF15 monoclonal antibody, and net cash of approximately $50M as of December 31, 2022. The combined company will continue to trade on Nasdaq under the ticker symbol "LPTX," will be led by Leap's existing management team, and will also remain focused on advancing DKN-01, Leap's anti-DKK1 monoclonal antibody, in Phase 2 clinical trials in gastric cancer, endometrial cancer, and colorectal cancer patients. The total cash balance of the combined company as of December 31, 2022 was approximately $115M, expected to be sufficient to fund Leap's planned operating expenses and development plans for DKN-01, FL-301, and the preclinical programs to mid-2025.

07:58 EST Forza X1 board authorizes $1M stock repurchase program - Forza X1 announced that its Board of Directors has approved a stock repurchase program authorizing the repurchase of up to $1,000,000 worth of shares of Forza X1, Inc. stock.

07:51 EST Bombardier launches new issuance of senior notes due 2029 - Bombardier announced that it has launched an offering of US$500 million aggregate principal amount of new Senior Notes due 2029. Bombardier intends to use the proceeds of the offering of the New Notes, together with cash on hand, to fund the redemption of all of its outstanding 7.500% Senior Notes due 2024, of which there is $396 million aggregate principal amount outstanding on the date hereof, to finance the offer to purchase up to $104 million aggregate principal amount of its outstanding 7.50% Senior Notes due 2025 of which there is $1,139 million aggregate principal amount outstanding on the date hereof, and for the payment of related fees and expenses. Consummation of the offering of the New Notes, the redemption of the 2024 Notes and the 2025 Tender Offer are subject to market and other conditions, and there can be no assurance that Bombardier will be able to successfully complete these transactions on the terms described above, or at all. The redemption of the 2024 Notes and the 2025 Tender Offer are subject to certain conditions, including the completion of the offering of the New Notes prior to February 16, 2023, as it relates to the 2024 Notes Redemption, and prior to February 1, 2023, as it relates to the 2025 Tender Offer.

07:49 EST Diana Shipping announces direct continuation of m/v Polymnia time charter - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has extended the time charter contract with CLdN Cobelfret , Luxembourg, for one of its Post-Panamax dry bulk vessels, the m/v Polymnia. The gross charter rate is US$10,000 per day for the first thirty days of the charter period and $15,000 per day for the balance period of the time charter, in each case minus a 5% commission paid to third parties, for a period until minimum April 1, 2024 up to maximum May 31, 2024. The new charter period commenced on January 14. The "Polymnia" is a 98,704 dwt Post-Panamax dry bulk vessel built in 2012. The Company also announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with Nippon Yusen Kabushiki Kaisha, Tokyo, for one of its Newcastlemax dry bulk vessels, the m/v Los Angeles. The gross charter rate is US$17,700 per day, minus a 5% commission paid to third parties, for a period until minimum May 20, 2024 up to maximum August 5, 2024. The charter commenced on January 15 .

07:46 EST OpGen gets confirmation from FIND of several key milestones met - OpGen announced that the Company has received confirmation from FIND, the global alliance for diagnostics, that several key milestones under its collaboration agreement with the global non-profit organization have been successfully met as of the end of 2022. This achievement has triggered an undisclosed milestone payment per the terms of the agreement.The completed milestone included several key deliverables: successful demonstration of DNA isolation on the Unyvero A30 cartridge from representative bacterial strains in various types of blood culture bottles with subsequent PCR; successful demonstration of several 3-plex assays from the intended panel on the A30 cartridge with both pathogen detection as well as AMR markers; and a detailed set of product requirements for the target product profile, including a list of analytes to be detected which has been defined. OpGen's subsidiary Curetis furthermore provided a report including results from its internal database analysis looking at genetic diversity and resistance profiles in pathogens observed in low and middle income countries. Also, a device specification for a prototype cockpit optimized for use with the A30 platform has been defined and agreed upon.

07:41 EST PyroGenesis in contract worth over over $500K with lithium-ion battery recycler - PyroGenesis Canada announces that the Company, through Pyro Green-Gas, a wholly owned subsidiary of PyroGenesis, has signed a contract with a North American lithium-ion battery recycler for the delivery of a system to decontaminate the dust generated during the battery recycling process. The value of the Contract must remain confidential, but the Company can confirm that it is it is over $500,000 and under $1M. Under the scope of this Contract, the Company has been engaged to design and fabricate a system with a volume capacity of up to 4000 Nm3/h. This represents the combined exhaust from (i) shredding battery materials, and (ii) handling and transfer via pneumatic conveying of the powdered and granular materials resulting from the Client's proprietary process.

07:40 EST Accuray's CyberKnife system used for first time in New Zealand - Accuray announced that Auckland Radiation Oncology is the first center in New Zealand to treat patients with the CyberKnife System, a robotic radiation therapy device known for delivering treatments with sub-millimeter precision and accuracy in typically 1 to 5 outpatient sessions. The ARO medical care team selected the CyberKnife S7 System to provide stereotactic radiosurgery and stereotactic body radiation therapy to patients.

07:38 EST Asahi Kasei collaborates to develop recycling technology for carbon fiber - Asahi Kasei has developed a new technology for recycling carbon fiber plastic compounds together with the National Institute of Technology, Kitakyushu College and Tokyo University of Science. Carbon fiber reinforced plastics, CFRP, are highly attractive for various industries in demanding application fields due to their unique balance of rigidity, mechanical strength and light weight. However, CFRPs are expensive and challenging from a recycling perspective, as it is difficult to extract the carbon fibers from the resin after usage. Together with its project partners at the National Institute of Technology at Kitakyushu College and the Tokyo University of Science, Asahi Kasei has developed a recycling method that allows carbon fibers to be extracted from CFRP or carbon fiber reinforced thermoplastics used in automobiles. This results in high-quality, inexpensive continuous carbon fiber that can be recycled perpetually, contributing to the circular economy. Unlike carbon fiber that is chopped up during the recycling process, Asahi Kasei's method allows carbon fiber to be extracted from a plastic compound seamlessly, resulting in continuous strands of carbon fiber that can be reapplied in exactly the same manner while retaining properties identical to the original substance.

07:37 EST Vision Marine Technologies and Four Winns team with new H2e Bowrider - "Vision Marine Technologies is joining forces with Four Winns, a division of Groupe Beneteau , to revolutionize the recreational boating market with their new H2e Bowrider, equipped with Vision Marine's E-Motion 180 HP fully electric powertrain and motor," said the companies. "The partnership between these two industry leaders represents a major step forward in the development of sustainable and high-performance electric boats. The combination of Four Winns' renowned boat design and Vision Marine cutting-edge technology results in a truly innovative and unparalleled product. The H2e Bowrider is a game-changer for recreational boating, offering a quiet and emission-free boating experience, while still delivering the power and speed that boaters crave. The E-Motion(TM) 180 HP fully electric powertrain provides smooth and instant torque, allowing for a thrilling and responsive ride. The public and the boating industry can look forward to a revolutionary new era of sustainable and high-performance boating with the H2e Bowrider and the partnership between Vision Marine and Four Winns," added the statement.

07:36 EST Asante announces results from drill program at Bibiani-Chirano mines corridor - Asante Gold announced results from its ongoing exploration drilling program at the South Russel and Aboduabo prospects located on our Bibiani - Chirano mines corridor on the Sefwi Greenstone Belt in Ghana. The Sefwi Greenstone Belt is host to significant gold mining operations including the Bibiani and Chirano mines which have produced +8Moz to date. Asante controls 53 km strike length of the corridor which includes the Bibiani and Chirano shear zones, where gold mineralization is typically hosted in shear faults and veins. The Company's Bibiani and Chirano gold mines have current mineral reserves of ~ 2.8Moz and Measured and Indicated resources of over 4.5Moz. The immediate exploration focus for Asante is to aggressively explore our proven mineralized trends to discover new mineable deposits and grow our mine and near mine resources and mine life. South Russel Prospect" The Company previously outlined the strike length of gold mineralization at South Russel as 200m, in its press release of August 17, 2022. New drilling results have now extended it to 500m. Drill intercepts confirm high grade mineralization from surface, consistent in width and grade to previous intercepts. The gold mineralized system remains open along strike and to depth. The South Russell prospect is located just 2 km south of the Bibiani Process Plant. Highlights: Recent drill intercepts include 21.5m down hole grading 3.37 g/t Au; of which 13.5m grades 5.05 g/t; Footprint of gold mineralization now tested and confirmed amounts to approximately 500m strike length and remains open along strike and to depth; Assay results continue to confirm significant intercepts from surface; All drill results are outside of the current mine plan mineral resource; Follow-up drill holes are planned to the south and north along strike of the recent intercepts. Selected intercepts include: MGDD22-194 - 21.5m @ 3.37 g/t Au from 22.0m to 43.5m Includes 13.5m @ 5.05 g/t Au from 24m to 37.5m; MGDD22-182 - 14m @ 4.49 g/t Au from 216m to 230m Includes 12m @ 5.20 g/t Au from 218m to 230m; MGRCD22-066 - 11.9m @ 3.22 g/t Au from 174.1m to 186m Includes 4m @ 7.53 g/t Au from 180m to 184m; MGRCD22-164 - 8m @ 3.36 g/t Au from 195m to 203m; MGDD22-105 - 7m @ 3.26 g/t Au from 171m to 178m; MGDD22-119- 5m @ 3.62 g/t Au from 177m to 182m; MGDD22-103 - 10m @ 1.86 g/t Au from 181m to 191m. Aboduabo Prospect: The Aboduabo prospect is located approximately 5km north of the Chirano Process Plant and 10 km south of the Bibiani Process Plant. It lies within the Bibiani trend, is hosted in Birimian sedimentary rock sequences, and is different in style compared to the Chirano gold deposits which are hosted in Birimian volcanic and granitoid sequences along the sub parallel Chirano trend. The historical exploration of the Aboduabo project comprised of 54 holes that delineated a mineralized strike of 1.3km and 500 meters wide. Significant gold assays. at shallow depth from surface, were noted in previous drilling programs. Some of the historical drill results include: Highlights: 24m down grading hole 4.31 g/t Au; 25m down hole grading 2.95 g/t Au; 23m down hole grading 2.65 g/t Au; 23m down hole grading 2.41 g/t Au; 32m down hole grading 2.17 g/t Au from CHRC1054 CHRC798D CHRC723 CHRC720 and CHCH009A respectively. Exploration activities at Aboduabo were initiated immediately after our recent acquisition of Chirano, with drill results acquired to date confirming that the mineralized system at Aboduabo is open for extension at depth and along strike. Drill results from the first hole of the current program have intersected 21.5m @ 2.99 g/t Au including 11.35m @ 4.73 g/t Au. The current drilling program was initiated in September 2022 and has been accelerated as Asante intends to prepare a maiden resource by Q4 2023 and, if warranted a starter pit soon thereafter.

07:34 EST Sidus Space expands distribution strategy through agreement with SkyWatch - Sidus Space announced that it signed an agreement with SkyWatch for use of its TerraStream data-management platform. This agreement is expected to accelerate the expansion of Sidus' commercial data distribution strategy which includes white labeling data for the Company's existing customers as well as driving growth of new data customers. Serving as a key contributor to the Space data marketplace, the agreement is expected to generate additional revenue for the Company and engage customers that otherwise may not have connected with Sidus. The TerraStream platform provides end-to-end data management and distribution capabilities to satellite operators, and provides an accelerated path to grow revenue and new markets through EarthCache, SkyWatch's remote sensing platform. "A key part of our business plan has always included monetizing high-impact data for insights on virtually every commercial sector, and, as we prepare to launch LizzieSat this year, this agreement represents an important milestone on that journey," said Carol Craig, Sidus Space Founder and CEO. "As new customers and industries begin to understand how Space-based data can impact business strategy, we believe that Sidus is well-positioned to capitalize on the increasing demand."

07:32 EST Solaris Resources reports assay results from Warintza Project - Solaris Resources reports assay results from a series of holes aimed at growing mineral resources at the Warintza East discovery within its Warintza Project in southeastern Ecuador. Highlights: Warintza East was discovered in July 2021, with eight holes covering the overlapping periphery included in the Warintza Central Mineral Resource Estimate in April 2022. These follow-up drill results significantly expand the drilled dimensions of the Warintza East footprint to the northeast, east and south, with the deposit remaining open in these directions, most importantly towards strong soil anomalism to the south. SLSE-16 was collared at the eastern limit of the grid and drilled southwest into an open volume, returning 108m of 0.57% CuEq within a broader interval of 712m of 0.45% CuEq from surface, extending mineralization to the south and southeast where it remains open This hole was collared approximately 250m to the southeast of SLSE-13, which previously returned 104m of 0.45% CuEq from surface within a broader interval of 618m of 0.29% CuEq; SLSE-17 was collared in the middle of the Warintza East drill grid and drilled southeast into an open volume, returning 144m of 0.52% CuEq from surface within a broader interval of 914m of 0.40% CuEq, extending mineralization to the east where it remains open; This hole extends the drilled dimensions further to the east beyond SLSE-14, which previously returned 292m of 0.50% CuEq from near surface within a broader interval of 694m of 0.40% CuEq; SLSE-19 was collared in the middle of the Warintza East drill grid and drilled northeast into an open volume, returning 270m of 0.40% CuEq from surface within a broader interval of 580m of 0.31% CuEq, expanding the footprint to the northeast where it remains open; Drilling to date confirms Warintza East as a significant porphyry deposit that adjoins Warintza Central and remains open for expansion, with assays pending from a series of extensional holes to the north, east, south and southeast. Jorge Fierro, Vice President, Exploration, commented: "Warintza East's largely undrilled footprint is a target for major mineral resource growth in the ongoing drilling program where only minimal drilling was included in the MRE and adjoins with Warintza Central. Assays are pending from further extensional holes to the north and east and targeting strong soil anomalism in step-out drilling to the south."

07:31 EST Eltek notified of $0.6M penalty from Ministry of Environmental Protection - Eltek received a notification from the Ministry of Environmental Protection about its intention to impose a penalty of approximately $0.6M for an alleged breach of the Clean Air Law during the years 2019-2020. The company intends to seek a reduction in the amount of the penalty, in accordance with provisions of the Clean Air Law.

07:31 EST Par Technology subsidiary announces $21M U.S. Navy Award - PAR Technology announced that the U.S. Navy has awarded its subsidiary, Rome Research Corporation, RRC, a five-year $21M contract to provide uninterrupted operations and maintenance, O&M, support at Camp Lemonnier, Djibouti, Africa, providing over 90% of Department of Defense, DoD, communications for the entire continent of Africa. RRC has supported the Camp Lemonnier facility since 2012. "For more than a decade, Rome Research Corporation has provided superior support to the Naval Computer and Telecommunications Area Master Station Atlantic site in Djibouti," Michael Nelson, President of PAR Government, said about its subsidiary's performance. "Our employees are very passionate about their roles in supporting DoD facilities. Our focus is on applying technology to continuously improve the operational effectiveness of our Nation's warfighters, and we are very excited to continue our partnership with NCTAMS LANT."

07:29 EST Tritium provides update on Tennessee factory operations - Tritium began its lease of a factory in Tennessee in March 2022, fit out the facility over five months with the first of six planned production lines operational in July, and held a grand opening in August. During the 2022 calendar year, the Company made meaningful upfront investments in raw materials, equipment, and the recruitment of more than 200 employees for the Tennessee facility. Tennessee will continue to scale over the course of 2023, producing the Company's chargers at a rate of efficiency previously not achievable. In December 2022, Tritium produced record units at both its Brisbane and Tennessee facilities, with each location contributing to the achievement of the single largest monthly output in Company history with more than 600 and 400 units, respectively. These milestones were reached by executing the Company's plan to accelerate production rates to meet customer demand and shorten order fulfillment time to drive improved working capital efficiency and advance Tritium's continued market leadership. Currently, the Tennessee factory is operating two production lines with plans to add three additional lines in 2023. While demand for Tritium's products supports an even faster factory ramp-up with additional lines and more shifts, the Company continues to balance its growth within the guardrails of working capital availability and labor recruitment in the local Tennessee market. The Company expects to hit several global production milestones in 2023 as the Tennessee factory continues to ramp-up and production at the Brisbane factory shifts to Tritium's new class of modular chargers. While the Tennessee factory focuses on modular charger production, Tritium remains on plan to cease production of its four legacy products at its Brisbane factory in 2023 to focus production efforts at that location solely on the Company's in-demand, modular chargers going forward. This optimization will further drive efficiency gains across purchasing, supply chain, warehousing, production, testing, quality control, and distribution, enabling improved margins. The production ramp-up in 2023 is expected to produce a total projected output of at least 11,000 units for the calendar year 2023. Calendar year 2024 is expected to benefit from the full year impact of 2023 initiatives: a production run rate at scale, the transition to the planned streamlined modular product suite, new products to be launched in 2023, continued improved pricing, and operational efficiencies across supply chains, logistics, and services.

07:25 EST Goldman Sachs reports Q4 FICC revenue $2.69B, up 44% y/y - Net revenues in Global Banking & Markets were $6.52 billion for the fourth quarter of 2022, 14% lower than both the fourth quarter of 2021 and the third quarter of 2022. Investment banking fees were $1.87 billion, 48% lower than a strong fourth quarter of 2021. Net revenues in Equities were $2.07 billion, 5% lower than the fourth quarter of 2021.

07:25 EST Goldman Sachs reports Q4 ROE 4.4%, ROTE 4.8% - Return on average common shareholders' equity was 10.2% for 2022 and annualized ROE was 4.4% for the fourth quarter of 2022. Return on average tangible common shareholders' equity was 11.0% for 2022 and annualized ROTE was 4.8% for the fourth quarter of 2022.

07:22 EST Immuron receives European patent on drug composition - Immuron announced that has been granted a European Patent for compositions and methods for the treatment and/or prophylaxis of Clostridioides difficile associated disease. Notification of the decision to grant European Patent 14784945.9, entitled "Methods and Compositions for the treatment and/or prophylaxis of Clostridium difficile associated disease," was formally received yesterday, and grant of this application will be published in the European Patent Bulletin on 25 January 2023 under European Patent No. 2986316. The company previously reported it had received notification from the European Patent Office of the intent to grant in July last year.

07:20 EST Osisko : Trixie portal underground decline completed to date - Osisko Development is pleased to announce an initial mineral resource estimate for its 100%-owned underground Trixie deposit , within the Company's wider Tintic Project , located in the historic East Tintic Mining District in central Utah, U.S.A. Chris Lodder, President of Osisko Development commented, "The initial Trixie MRE reflects a very limited footprint of the historically defined mineralized zones at Trixie and was delineated within only six months of the acquisition of the project. It exhibits outstanding precious metal grade potential within the structural corridors of the host quartzite and based on all data received and compiled to date we see potential to continue to extend mineralization at depth and on strike throughout and parallel to the historic mine footprint as well as repeats at several other prospects and past producers in the East Tintic District. This resource will assist the Company with its near-term exploration and operational planning."The Trixie MRE comprises five mineralized zones within the greater Trixie deposit, including T1, T2, T3, T4 and 75-85 zones over a strike length of 610 meters, a maximum width of 105 m and to a maximum depth of 295 m.The Trixie MRE is based on 4,467 underground chip samples, 4,780.1 m of current and verified historic drilling in 50 holes, of which 3,228.9 m of drilling in 23 holes were drilled by the Company in 2022. Gold mineralization is associated with high sulphidation epithermal mineralization, structurally controlled, and hosted within the quartzites. Mineralization consists of native Au, and rare Au-Ag rich telluride minerals with quartz and quartz-barite-sulphosalt stockwork veining...Approximately 50% of the 1,390 meter Trixie portal underground decline ramp has been completed to date. On track to reach the 625 level by the second quarter of 2023.The decline will significantly improve access to the underground workings, expand potential underground exploration target areas and provide sufficient flexibility to complete additional programs targeting mineral resource growth potential beyond the 625 level.

07:20 EST Vertex Energy provides update on its Q4 financial results - Vertex Energy provided an update on its fourth quarter 2022 operating and financial results. Throughput volumes at the Company's Mobile Refinery for the fourth quarter of 2022 came in at approximately 77 Mbpd, exceeding management's prior forecast of 73 - 75 Mbpd, by 4% at the mid-point. The stronger throughput volumes for the quarter versus the Company's previously communicated estimates reflect continued consistent, efficient operations at the Mobile Facility. Operating expenses per barrel for the fourth quarter of 2022 are estimated to total between $3.75 - $4.00 per barrel, while the targeted capture rate on the benchmark Gulf Coast 2-1-1 crack spread is expected to be 50%-54%, in-line with prior forecasts. Based on performance during the quarter, Vertex is updating the prior guidance provided for 4Q 2022 as follows: Mobile Refinery Throughput Volume: raised to 77 from 73-75. Capex raised to $42M from $35M-$40M.

07:17 EST Lifeist's Mikra to begin production on nutritional bars in late spring 2023 - Lifeist Wellness announced that its U.S. biosciences subsidiary Mikra Cellular Sciences will expand into the health food and snacks product category. With the research & development phase complete, Mikra expects to begin production of nutritional bars in late spring 2023 with products available for purchase by consumers in the second half of the year. The first foray for Mikra into health food and snacks will be a certified gluten-free, vegan, functional nutrition bar targeting intermittent fasters in need of a low glycemic index meal to break their fast and health-conscious individuals looking for a clean, substantial snack to maintain energy between meals. Mikra's debut in this mainstream vertical steps outside of the nutraceuticals category it is currently known for, expanding visibility and consumer targeting to reach a broader audience and grow its customer base in a variety of directions, maximizing potential for long term growth and overall brand resonance.

07:15 EST EyePoint reports inducement grants under Nasdaq listing rule - EyePoint Pharmaceuticals announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2016 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 4,000 shares of EyePoint Pharmaceuticals common stock to two new employees. The stock options were granted on January 13, 2023. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $5.04 per share, the closing price of EyePoint Pharmaceuticals' common stock on January 13, 2023. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's date of grant and the remainder vesting in equal monthly installments over the following three years. Vesting of the options is subject to the employee's continued service with EyePoint Pharmaceuticals through the applicable vesting dates.

07:14 EST Munich Re selects Verisk Maplecroft to enhance human rights due diligence - Munich Re has selected Verisk's global risk analytics business, Verisk Maplecroft, to help it enhance human rights due diligence across the entire enterprise. Using Verisk Maplecroft's world leading Human Rights Risk Indices, which identify exposure to 31 civil, political and labour rights risks at national and subnational levels in 198 countries, Munich Re will upscale its ability to undertake global operational risk assessments, alongside factoring the data into its underwriting and investment decisions.

07:13 EST Hecla reports union ratification of six-year agreement at Lucky Friday Mine - Hecla Mining Company announced that the United Steelworkers, USW, Union Local 5114 has ratified the Collective Bargaining Agreement at the Company's Lucky Friday Mine, located in Mullan, Idaho. The USW Local 5114 and the Company have agreed to a 6-year contract. The work rules were largely unchanged from the prior agreement. Wages are increased to reflect recent inflationary pressures and to maintain Lucky Friday's competitiveness in a tight labor market. "With the ratification of this 6-year agreement, Lucky Friday is positioned for continued successful growth well into the future", said Phillips Baker, Jr., President & CEO. "The agreement shows the strong working relationship with the USW Local 5114 and gives both the work force and Hecla stability. With 2022's 24% increase in silver production over 2021 and the expected further growth in the coming years, we believe this decade will be the best in the mine's 80-year history."

07:11 EST Tritium says BP has placed largest order in company history - Tritium DCFC announced that bp has placed the largest ever order from a single customer in Tritium's history. bp will install the chargers for fleets and the general public in the United States, the United Kingdom, Europe, and Australia as bp expands its EV charging business, bp pulse. Tritium is supplying the chargers for bp pulse as part of a multi-year contract between the two companies, announced in April 2022, for chargers and related services to support bp's growth in electrification. bp's order includes a mix of Tritium's 50kW RTM and 150kW PKM chargers. Tritium's RTM is the company's first modular charger and one of the most advanced DC fast chargers on the market. Ideal for network operators, dealerships, and the retail and hospitality industries, the RTM uses a single person lift power module system for easier power upgrades, maintenance, and serviceability.

07:10 EST 908 Devices unveils new glucose, lactate on-line device - 908 Devices announced the launch of MAVEN, a device for on-line monitoring and control of glucose and lactate in cell culture and fermentation processes. MAVEN empowers biopharma companies to make timely decisions based on highly sensitive, real-time measurements. Taking measurements as frequently as every two minutes, MAVEN operates without having to manually draw samples out of the bioreactor due to its novel aseptic sampling approach. "As more advanced therapies enter the pipeline there is an increasing need for simple, automated on-line devices like MAVEN for measuring and monitoring process and product attributes," said Dr. Kevin Knopp, CEO and co-founder, 908 Devices. "MAVEN's incorporated aseptic sampling probe serves as an interface for future on-line analyzers as we broaden our bioanalytics platform and develop an ecosystem of connected, on-line tools."

07:09 EST Draganfly selected by Lufthansa Industry Solutions for drone, VI technology - Draganfly (DPRO) announced that Lufthansa Industry Solutions (DLAKY) has entered into a letter of intent with Draganfly to explore providing its drone solutions and Vital Intelligence technology for use into its existing infrastructure and customer solutions. Draganfly's technology will assist in Lufthansa Industry Solutions' objective of providing the maritime industry with the highest information technology and performance monitoring standard. Draganfly's drone solutions will be integrated for deployment during marine search and rescue operations and for reconnaissance purposes, adding another layer of safety and security for crew members and passengers.

07:08 EST Welltower announces executive and senior leadership promotions - Welltower announced executive and senior leadership team promotions. Nikhil Chaudhri was appointed Executive VP - Chief Investment Officer and a member of Welltower's Investment Committee after previously serving as Senior VP and Co-Head of US Investments. Chaudhri joined Welltower eight years ago as an associate. Ayesha Menon was appointed Executive VP - Wellness Housing and Development, after driving the company's wellness housing growth initiatives for the past four years as Senior Vice President- Wellness Housing and Development and a member of Welltower's Investment Committee. Swagat Banerjee was promoted to Chief Data Officer after previously serving as Senior VP - Data & Insights. Banerjee has led the growth of Welltower's data analytics platform over the past seven years. Russ Simon was promoted to Senior VP, Co-Head of US Investments and named to Welltower's Investment Committee. Simon joined Welltower 12 years ago as an investment analyst and now leads the company's investments in the medical office and seniors housing sectors. The company promoted Andrew Cohen to Co-Head of US Investments. Cohen joined Welltower five years ago as an associate and now leads investments in the wellness housing and seniors housing sectors. Sharon Makowsky was promoted to Deputy General Counsel of Welltower and named a member of the senior leadership team.

07:05 EST Altair Engineering: Soltec to adopt Altair technology in R&D division - Altair announced that Soltec, a global solar equipment manufacturer based in Murcia, Spain, will be utilizing Altair technology within its research and development division. This represents a significant win in the solar energy sector for Altair.

07:04 EST CBRE Group and Forum Mobility form $400M JV for port transit electrification - CBRE Group and Forum Mobility, a zero-emission trucking solutions provider, announced the closure of a $15M Series A funding round, and a new $400M joint venture, both led by a fund sponsored by CBRE Investment Management, to provide comprehensive, zero-emission charging and vehicle solutions to drayage truck fleets and drivers. Homecoming Capital also participated in the Series A funding round and provided $100M to the joint venture. Currently proposed regulations from the California Air Resources Board would require all of California's drayage fleet - approximately 30,000 trucks - to be zero-emission by 2035. Forum Mobility's existing seed investors all participated in the Series A, including Obvious Ventures, Edison International, Overture, and Homecoming Capital. New Series A investors include CBRE Investment Management, Elemental Excelerator and Amazon's Climate Pledge Fund.

07:03 EST SSR Mining appoints Swager to board of directors - SSR Mining (SSRM) announces the appointment of Karen Swager to its Board of Directors. Swager brings over 28 years of experience in the mining industry to the Board. Currently, Swager serves as Senior Vice President, Supply Chain for the Mosaic Company (MOS).

07:02 EST Emerson Electric 'disappointed' National Instruments chose to announce review - The company said, "Emerson is disappointed that NI chose to announce a strategic review and put in place a poison pill on January 13, 2023, rather than engaging privately and constructively. NI did not respond to Emerson's latest letter sent on January 11 before its public announcement. NI's strategic review announcement comes more than two months after the NI Board purportedly formed a working group to evaluate options with its advisors - with no results. NI shareholders should understand that for eight months they have been deprived of the opportunity to realize certain cash value at a significant premium. Emerson urges NI shareholders to engage with their Board to ensure this public strategic review process is not merely another delay tactic. Emerson has organized the resources to work expeditiously toward a transaction with NI, has shared a merger agreement with NI, and is prepared to transact promptly. Emerson has performed due diligence with publicly available information and would have only limited and specific confirmatory due diligence requirements. Additionally, Emerson does not anticipate any significant regulatory risks or delays given the complementary nature of the two businesses. Finally, the Emerson proposal is not subject to any financing conditions. Emerson feels compelled to disclose the contents of all its correspondence with NI, beginning in May 2022, to make public its consistent and sustained track record of attempted engagement with NI, without any meaningful or constructive response."

07:00 EST Emerson says National Instruments resisted 'engaging meaningfully' on offer - The company said, "Emerson's first outreach to NI regarding a potential all-cash acquisition was on May 16, 2022, and Emerson's initial $48 per share proposal was formalized in a letter on May 25, 2022. For eight months, NI delayed and refused to engage meaningfully with Emerson. In addition, after receiving the initial May 25, 2022 proposal from Emerson, NI not only refused to engage with Emerson - it repurchased more than 2 million shares at an average weighted price of $40.25, the largest quarterly repurchase in its history on a dollar basis, depriving its shareholders of the opportunity to realize immediate cash value through the transaction price, which is significantly above the repurchase price. In a November 3, 2022 letter, Emerson outlined the terms of an improved all-cash proposal of $53 per share and highlighted its numerous attempts to engage with NI to that date. On November 15, 2022, NI responded to Emerson, indicating that it had created a working group of its Board to examine Emerson's proposal in greater detail, as well as evaluate options with the assistance of advisors. In the more than two months since, NI continued to resist engaging meaningfully with Emerson to work toward an agreement. Eight months after Emerson's approach, NI agreed to a January 4, 2023 meeting with representatives from Emerson, which was followed by one additional conference call. During these discussions, NI shared very limited, high-level information about its business and continued to demonstrate its unwillingness to provide more detailed information, including refusing to respond to key diligence questions provided ahead of the meeting. NI then informed Emerson that this would be the extent of its engagement. In a letter dated January 11, 2023, Emerson reiterated its $53 per share proposal to acquire NI."

06:56 EST Emerson submits proposal to acquire National Instruments for $53 per share

06:51 EST Jefferies Financial completes spin-off of Vitesse - Jefferies Financial (JEF) and Vitesse (VTS) announced the completion of the distribution by Jefferies of all the outstanding shares of common stock of Vitesse held by Jefferies. As a result of the distribution, Vitesse became an independent, publicly traded company. Prior to the distribution, Vitesse acquired all of the issued and outstanding equity interests of Vitesse Energy and Vitesse Oil. Common shares of Jefferies and Vitesse Common Stock will each begin trading "regular way" January 17 on the NYSE under the symbols "JEF" and "VTS," respectively. In connection with the Distribution, on January 13, 2023, Jefferies shareholders received one share of Vitesse Common Stock for every 8.49668 Jefferies Common Shares held at the close of business on December 27, 2022. Fractional shares will be aggregated and sold into the public market and the proceeds distributed pro rata to Jefferies shareholders who otherwise would have received such fractional shares. Approximately 26.6 million shares of Vitesse Common Stock were distributed to Jefferies shareholders, which equals approximately 94.37% of the total issued and outstanding shares of Vitesse Common Stock.

06:47 EST Pfizer expands commitment to 'An Accord for a Healthier World' - Pfizer announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccines for which it has global rights on a not-for-profit basis to enable greater health for 1.2B people living in 45 lower-income countries. Launched in May 2022, the Accord, a transformative initiative focused on greatly reducing health inequities that exist between many lower-income countries and the rest of the world, initially included a commitment from Pfizer for access to all its patented medicines and vaccines available in the U.S. or European Union on a not-for-profit basis to 45 lower-income countries. However, to better align with disease burden and unmet patient needs in these countries, Pfizer will now expand its offering under the Accord to include off-patent products, bringing the total offering from 23 products to around 500 products. The Accord portfolio offering now includes both patented and off-patent medicines and vaccines that treat or prevent many of the greatest infectious and non-communicable disease threats faced today in lower-income countries. This includes chemotherapies and oral cancer treatments that have the potential to treat nearly one million new cancer cases in Accord countries each year. It also includes a wide range of antibiotics, that can help to address the rising morbidity, mortality and costs associated with antimicrobial resistance and help to prevent around 1.5M deaths that occur each year in these countries as a result of bacterial infections in hospitals and community health clinics. As Pfizer launches new medicines and vaccines, those products will also be included in the Accord portfolio on a not-for-profit basis.

06:33 EST Calyxt, Cibus enter definitive all-stock merger agreement - Calyxt and Cibus announced that both companies have entered into a definitive merger agreement under which Calyxt and Cibus will merge in an all-stock transaction. The companies said, "The merger will create a new industry-leading company that combines the two pioneers in agriculture-based gene editing and establishes one of the world's most sophisticated facilities for trait development and next-generation plant breeding. The combined company will be a leader in two key applications for gene editing in agriculture: Productivity Traits: Productivity traits are a key basis of competition in the "seed and trait" business. The key focus of Cibus' patented gene editing platform, the Rapid Trait Development System, is the development of a new class of productivity traits in seeds addressing the sustainability of farming by increasing crop yields and reducing inputs such as fungicides, herbicides, pesticides, and fertilizers. Renewable Low-Carbon Ingredients: Gene editing is a key tool in the development of sustainable low-carbon ingredients that can replace fossil fuel-based ingredients and diesel fuel. This is a key pillar of the Net Carbon Zero Climate 2040 goals and the global movement to reduce greenhouse gas emissions." Cibus has a broad pipeline of productivity traits and collaborations with several leading seed companies. It is currently launching three important productivity traits: one in canola and two in rice with transfers to customers for commercialization beginning in the first half of 2023. In addition, Cibus and Calyxt are both working with leading consumer product companies to develop more sustainable ingredients. Under the terms of the merger agreement, Calyxt will issue shares of its common stock to Cibus shareholders in an exchange ratio such that upon completion of the merger, Calyxt shareholders will own approximately 5% of the combined company, subject to adjustments permitted by the merger agreement. The Boards of Directors of both companies have unanimously approved the transaction. Concurrent with the execution of the merger agreement, certain officers of Calyxt, all of Calyxt's directors, and Cellectis, S.A., Calyxt's largest shareholder, executed support agreements in favor of the merger. These support agreements provide 49.9% approval from Calyxt shareholders. A majority of Cibus' shareholders have also provided support agreements in favor of the transaction. The merger is expected to close in the second quarter of 2023, subject to customary closing conditions, including approval of the merger by the shareholders of Calyxt. Upon closing of the transaction, the combined company, renamed Cibus Inc., will trade on the Nasdaq Capital Market. The current Cibus management team will lead the new combined organization with Rory Riggs assuming the roles of Chairman of the Board of Directors and CEO. Corporate headquarters for the combined company will be located in San Diego, California and Calyxt's offices, laboratory, and breeding facilities in Roseville, Minnesota will remain operational as a key site for the combined company.

06:25 EST Fortuna Silver Mines sees 2023 gold eq. production up 3%-15% year-over-year - Fortuna Silver Mines provided 2023 consolidated production guidance highlights. The company projects gold production of 282-320 thousand ounces; a projected increase of 9%-23% over 2022; silver production of 6.3-6.9 million ounces, a projected decrease of up to 9% over 2022; gold equivalent production of 412-463 thousand ounces, a projected increase of between 3%-15% over 2022.

06:20 EST BIT Mining launches LiteCoin/Dogecoin miner LD3 - BIT Mining announced the launch of their Litecoin / Dogecoin mining machine, model LD3, which was specifically designed for mining on the DOGE and LTC blockchains. The company said, "The power efficiency of 0.73 W/MH and 4800 MH/s delivery make the LD3 machine more profitable than its predecessors in terms of efficient energy consumption. As a result, it is one of a few cutting-edge products available that deliver a highly cost-effective performance while offering the shortest payback period for LTC/DOGE mining. The machines are designed for reliability, with the LD3s leaving more than a 10% performance margin for computing power chips rather than driving the machine to work under extreme conditions. This practice not only effectively prolongs the need to service the machine but also enables LD3s to work more consistently, resulting in reduced maintenance costs. Furthermore, the design of LD3 provides more security guarantees for LTC/Doge miners. LD3 machine implements software-level security mechanisms with the latest common vulnerabilities & exposure patches. In addition, hardware-level protections for security are also implemented." Currently, over 5,000 of the new LD3 miners have been produced for both Bit Mining's internal use and sale to the public.

06:17 EST Avista turning over Montana power plant interests to NorthWestern Energy in 2025 - Avista (AVA) and NorthWestern Energy (NWE) entered an agreement through which Avista will turn over its interest in the Colstrip coal-fired power plant to NorthWestern on December 31, 2025. Through the transaction, NorthWestern will assume ownership of the 222 MW generating capacity that is currently owned by Avista, along with its related interest in the plant, plant equipment, rights and obligations. Avista's integrated resource plan has indicated that Colstrip will no longer be economic for its customers in Washington and Idaho after 2025. Under the agreement, Avista retains its existing remediation obligations and enters into a vote sharing agreement with NorthWestern to retain voting rights in regard to any decision that might be made with respect to remediation activities. In addition, while NorthWestern will have the right to exercise Avista's vote with respect to capital expenditures between now and 2025, Avista's contribution to those expenditures is limited to its pro rata share between the date of the expenditure and 2025, ensuring that the costs directly benefit Avista customers and don't extend the life of the plant. The Agreement also preserves Avista's rights in the Colstrip transmission system, giving Avista the ability to leverage capacity on that system for future renewables projects in furtherance of its clean energy goals. Each of the owners will have a 90 day period in which to evaluate the transaction and determine whether to exercise their respective right of first refusal as to a portion of the generation being turned over to NorthWestern.

06:13 EST Filecoin Foundation to deploy IPFS in space via Lockheed Martin spacecraft - Filecoin Foundation announced a first-of-its-kind mission to deploy the Interplanetary File System in space. The mission will take place in 2023 aboard Lockheed Martin's LM 400 Technology Demonstrator spacecraft. Previously, in May 2022 in Davos, FF announced an initial effort with Lockheed Martin to deploy IPFS in space to improve the speed of data transfer across long distances. This mission is the next step in that project, bringing the benefits of decentralized storage to space and exploring use cases for how IPFS can enable better interplanetary communication and data transfer.

06:11 EST PureCycle Technologies to build PP recycling facility in Port of Antwerp-Bruges - PureCycle Technologies and the Port of Antwerp-Bruges announced that PureCycle intends to build its first polypropylene recycling facility in Europe in the port's NextGen District located in Belgium. The new plant is expected to have an annual capacity of 59,000 metric tons, with opportunities to expand operations in the future since the 14-hectare plot can support up to four processing lines with an anticipated total capacity of approximately 240,000 metric tons per year. PureCycle is currently engaged in feedstock sourcing and financial planning with the intent to secure a final project timeline by mid-2023. Construction of the plant is expected to begin upon completion of the permitting process, which is currently anticipated in 2024. PureCycle is already in active negotiations with potential feedstock and offtake partners and expects to commence commercial operations at its new European facility when construction of the first processing line is completed. The new polypropylene purification plant will not only supply the European market with PureCycle's UPR resin but is also expected to create 65-70 new jobs for local residents during the initial phase of the project. This project represents one of the largest investments announced in the NextGen District to date. Various funding options are currently being considered, including traditional financing sources as well as grants/subsidies for circular projects that are uniquely available in the EU.

06:10 EST Centerra Gold reports Q4 production 53,222 oz. - Reports Q4 copper production 16.9 million pounds. Q4 gold production was solely from the Mount Milligan Mine. 2022 gold production was 246.468 oz. including 189,177 ounces of gold produced by the Mount Milligan Mine and 54,691 ounces produced by the Oksut Mine. Additionally, approximately 100,000 recoverable ounces was processed into gold-in-carbon form in 2022 and remains stored at the Oksut Mine. Copper production was 16.9 million pounds in Q4 and 73.9 million pounds for the full year 2022.

06:09 EST DexCom says coverage for G6 rtCGM System on NIHB Program expanded - Dexcom is pleased to announce that coverage for Dexcom G6 rtCGM System on the Non-Insured Health Benefits Program has been expanded to include all clients living with type 1 diabetes. This announcement expands upon coverage already in place for clients aged 2 to 19 on intensive insulin therapy, giving even more First Nations and Inuit people access to this standard of care, potentially helping them to have more control over a life-long chronic illness.

06:07 EST CF Industries signs MOU to supply Japan's JERA with clean ammonia - CF Industries has signed a memorandum of understanding - MOU - with JERA, Japan's largest energy generator, regarding the supply of up to 500,000 metric tons per year of clean ammonia beginning in 2027. The clean ammonia, which will be required to be produced with at least 60% lower carbon emissions than conventionally produced ammonia, will be co-fired with coal at JERA's Hekinan Thermal Power Station in order to reduce carbon dioxide emissions from the facility. The MOU establishes a framework for the companies to assess how CF Industries would best supply JERA with clean ammonia under a long-term offtake agreement. Since 2020, CF Industries has advanced projects to decarbonize its ammonia production network and position the company to supply a substantial volume of clean ammonia within the next few years.

06:05 EST Stellantis, Vulcan sign binding term sheet to develop new geothermal projects - Stellantis and Vulcan Energy Resources have signed a binding term sheet for the first phase of a multiphase project to develop new geothermal projects aimed at decarbonizing the energy mix of Stellantis' Russelsheim industrial site in Germany, which is home to both the DS4 and Opel Astra. Based upon current assumptions, the project could provide a significant portion of the industrial site's annual energy needs starting in 2025. The first phase of the project, located at the northernmost extent of Vulcan's focus area in the Upper Rhine Valley, will include a pre-feasibility study for the construction of geothermal assets for Stellantis' facility, carried out by Vulcan. If successful, the next phase will focus on drilling and more advanced studies and development. Stellantis will aim to source funding for 50% of the project development, which is also supported by the local government. Stellantis and Vulcan will aim to produce clean electricity and supply it to the grid for both internal and external consumption, in accordance with Germany's Renewable Energy Act, while also producing heat to be transferred to Stellantis' manufacturing site.

05:57 EST Dragon Victory changes name to Metalpha Technology Holding - Dragon Victory International (LYL) announces it has officially changed its name to Metalpha Technology Holding (MATH). The company has also successfully completed restructuring with Antalpha Technologies Limited. Upon completion of the reorganization, Metalpha Limited will become a wholly-owned subsidiary of the company. Established in 2021, Metalpha is a leading digital assets wealth management company headquartered in Hong Kong. The company works with clients to create tailor-made instruments that enable sophisticated investors to establish or liquidate investment positions or undertake hedging strategies.

05:50 EST Whirlpool completes EMEA review, enters agreement with Arcelik - Whirlpool announced the completion of the strategic review of its Europe, Middle East and Africa business and entered into a definitive contribution agreement with Arcelik. which significantly accelerates Whirlpool's portfolio transformation. Under the terms of the agreement, Whirlpool will contribute its European major domestic appliance business, and Arcelik will contribute its major domestic appliance, consumer electronics, air conditioning, and small domestic appliance businesses into the newly formed entity of which Whirlpool will own 25% and Arcelik 75%. Separately, Whirlpool agreed in principle to the sale of Whirlpool's Middle East and Africa business to Arcelik. Whirlpool will retain ownership of its EMEA KitchenAid small domestic appliance business. The new entity is expected to have combined sales of over EUR6B and will be well-positioned to deliver value to consumers through attractive brands, sustainable manufacturing, product innovation, and consumer services. The combined businesses are expected to generate cost synergies of over EUR200M. The transaction announced today is expected to deliver net present value of future cash flows of over $750M, primarily through predictable cash flows from multi-year licensing of the Whirlpool brand and the potential monetization of Whirlpool's minority interest. As previously announced, Whirlpool separately sold its Russia business to Arcelik in August of 2022 for up to $260M of deferred payments. The Russia business will not be part of the new combined company. Post closing, Whirlpool expects full-year cash provided by operations and free cash flow to increase by approximately $100M and $250M, respectively, in addition to future proceeds from a licensing agreement entered into in connection with the transaction and any dividends from the new entity. The transaction is expected to close in the second half of 2023 and is subject to additional requirements for closing, including obtaining regulatory approvals and other customary closing conditions. In connection with the transaction, the company recorded a non-cash loss on disposal of approximately $1.5B in the fourth-quarter of 2022. The loss includes a charge of approximately $1.1B for the write down of the net assets of the EMEA business to the fair value of the initial consideration to be received and approximately $400M of cumulative currency translation adjustments. The transaction is expected to negatively impact full-year 2022 earnings per share by approximately $26.00 to $28.00 on a GAAP basis with no expected material impact on an ongoing (non-GAAP) basis. Whirlpool's European business met the criteria for held-for-sale accounting during the fourth-quarter of 2022. Until the closing of the transaction, Whirlpool's European business will be included in the company's results. Additionally, Whirlpool will have no obligation to provide financing to the new company after the transaction closes.